Sentence,class,file
J Inter- feron Cytokine Res 2011; 31:393–400; PMID:21194349; http://dx.doi.org/10.1089/jir.2010.0069 37.,OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
PLoS One 2013; 8(1): e52198; PMID:23326326; http://dx.doi.org/10.1371/journal.pone.0052198 38.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
Immunol Rev 2012; 247:52–63; PMID:22500831;http://dx.doi.org/10.1111/j.1600-065X.2012.01124.x 40.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
Vaccine 1994 Aug; 12(11):993–9; PMID:7975853; http://dx.doi.org/ 10.1016/0264-410X(94)90334-4 41.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
J Infect Dis 1995 Jan; 171(1):198–203; PMID:7798664; http://dx.doi.org/10.1093/infdis/171.1.198 42.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
"IgA, IgA subclasses, and secretory component levels in oral ﬂuid collected from subjects after parental inﬂuenza vaccination.J Infect Dis 1995 Apr; 171(4):1072–4;PMID:7706797; http://dx.doi.org/10.1093/infdis/ 171.4.1072-a 43.",Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
Scand J Immunol 2001 Jul–Aug; 54(1–2):243–7; PMID:11439173; http://dx.doi.org/10.1046/j.1365- 3083.2001.00947.x 44.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
Vaccine 2003 Dec 8; 22 (1):57–63; PMID:14604571; http://dx.doi.org/ 10.1016/S0264-410X(03)00540-1 46.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
J Biol Chem 1998; 273:16968–75; PMID:9642260;http://dx.doi.org/10.1074/jbc.273.27.16968 47.,OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
Mol Syst Biol 2013; 9:659;PMID:23591775; http://dx.doi.org/10.1038/ msb.2013.15 48.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
Nat Immunol 2013; 14:480–8; PMID:23525089; http://dx.doi.org/10.1038/ni.2563 49.,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
Nature 2008; 451:1069–75; PMID:18305538; http://dx.doi.org/10.1038/nature06639 1672 Volume 11 Issue 7 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/09/69/khvi-11-07-1032486.PMC4514187.pdf
"Among initially seronegative girls in t he ATP-I, neutralizing antibody titers we re at least 1.8-fold higher for HPV-16/18 © Ting Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, Damien Friel, Benoit De Muynck, St /C19ephanie De Simoni, Pemmaraju Suryakiran, Marjan Hezareh, Nicolas Folschweiller, Florence Thomas, and Frank Struyf *Correspondence to: Ting Fan Leung; Email: t ﬂeung@cuhk.edu.hk Submitted: 03/16/2015; Revised: 04/23/2015; Accepted: 05/08/2015 http://dx.doi.org/10.1080/21645515.2015.1050570 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Disclosure of Potential Conﬂicts of Interest All authors have completed the Uniﬁed Competing Interest form at http://www.icmje.org/coi_disclosure.pdf and declare thefollowing potential conﬂicts of interest.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
"Hum Vaccin 2009; 5:705-19; PMID:19684472; http://dx.doi.org/10.4161/ hv.5.10.9518 2. de Sanjos /C19e S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al.",Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8 3.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Int J Cancer 2011; 128:927-35; PMID:20473886; http://dx.doi.org/10.1002/ijc.25396 4.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Available from: http://www.hpvcentre.net/statistics/ reports/XWX.pdf.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
JAdolesc Health 2007; 40:564-71; PMID:17531764; http://dx.doi.org/10.1016/j.jadohealth.2007.02.015 6.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Pediatrics 2006; 118:2135-45; PMID:17079588; http://dx.doi.org/ 10.1542/peds.2006-0461 7.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet 2004; 364:1757- 65; PMID:15541448; http://dx.doi.org/10.1016/ S0140-6736(04)17398-4 8.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet 2006; 367:1247-55; PMID:16631880; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4 10.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet Oncol 2012; 13:89-99; PMID:22075171;http://dx.doi.org/10.1016/S1470-2045(11)70286-811.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx.doi.org/10.1016/S1470-2045(11)70287-X 12.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Infect Dis 2007; 196:1438-46; PMID:18008221; http://dx.doi.org/10.1086/522864 13.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet 2007;369:1861-8; PMID:17544766; http://dx.doi.org/ 10.1016/S0140-6736(07)60852-6 14.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Hum Vaccin2011; 7:1374-86; PMID:22048171; http://dx.doi.org/ 10.4161/hv.7.12.18322 15.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Hum VaccinImmunother 2014; 10:1155-65; PMID:24576907; http://dx.doi.org/10.4161/hv.28022 17.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
JAMA 2013; 309:1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625 18.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Available from: http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/ 10.1016/S0140-6736(07)60946-5 21.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Vaccine 2012; 30Suppl 5:F139-48; PMID:23199957; http://dx.doi.org/ 10.1016/j.vaccine.2012.05.039 23.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Vaccine 2013; 31:1673-9; PMID:23375978; http://dx.doi.org/10.1016/j.vaccine.2013.01.028 24.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Prev Med 2014; 61:20-5; PMID:24440159; http://dx.doi.org/10.1016/j.ypmed.2014.01.007 25.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Hum Vaccin Immunother2014;10:3435-45; PMID:25483701; http://dx.doi.org/ 10.4161/hv.36121 26.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
PLoS One 2013; 8: e61825; PMID:23650505; http://dx.doi.org/10.1371/journal.pone.0061825 27.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Infect Dis 2014; 209:1165-73; PMID:24273179; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Vaccine 2014;32:5357-62; PMID:25045814; http://dx.doi.org/ 10.1016/j.vaccine.2014.07.014 29.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Infect Dis2014; 210:517-34; PMID:24610876; http://dx.doi.org/ 10.1093/infdis/jiu139 30.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Natl Cancer Inst 2010; 102:1653-62; PMID:20944077; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Science 2002; 298:2199- 202; PMID:12481138; http://dx.doi.org/10.1126/ science.1076071 32.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Immunol 2003; 171:4969-73; PMID:14607890; http://dx.doi.org/ 10.4049/jimmunol.171.10.4969 33.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Vaccine 2003; 21 Suppl 2:S35-7;PMID:12763680; http://dx.doi.org/10.1016/S0264- 410X(03)00198-1 34.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Pharmacoepidemiol Drug Saf 2014; 23:466-79; PMID:24644063; http://dx.doi.org/10.1002/pds.3554 35.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Pharmacoepidemiol Drug Saf 2014; 23:456-65; PMID:24644078; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
PediatrInfect Dis J 2010; 29:95-101; PMID:19952863; http://dx.doi.org/10.1097/INF.0b013e3181b77906 37.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Expert Rev Vaccines2007; 6:723-39; PMID:17931153; http://dx.doi.org/ 10.1586/14760584.6.5.723 38.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
BioDrugs 2011; 25:217-26; PMID:21815697; http://dx.doi.org/10.2165/11591760- 000000000-00000 39.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Vaccine 2006; 24:5937-49; PMID:16828940; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Hum Vaccin 2007; 3:139-45; PMID:17581283; http://dx.doi.org/10.4161/hv.3.4.4309 41.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Hum Vaccin 2008; 4:425-34; PMID:18948732; http://dx.doi.org/10.4161/hv.4.6.6912 42.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Front Oncol 2014; 3:328;PMID:24455487; http://dx.doi.org/10.3389/fonc.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Virology 2004; 321:205-16; PMID:15051381; http://dx.doi.org/10.1016/j.virol.2003.12.027 44.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Immunol Methods 2004; 286:111-22; PMID:15087226; http://dx.doi.org/10.1016/j.jim.2003.12.015 45.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Hum Vaccin 2011; 7:1343-58; PMID:22048173; http://dx.doi.org/10.4161/hv.7.12.18281 46.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Clin Immunol 2011; 31:443-54;PMID:21174144; http://dx.doi.org/10.1007/s10875- 010-9490-6 47.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
J Immunol Methods 2007; 323:39-54; PMID:17451739; http://dx.doi.org/10.1016/j.jim.2007.03.002 48.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Nat Protoc 2006; 1:1-6; PMID:17406204; http://dx.doi.org/10.1038/nprot.2006.1 49.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Nat Med 2005; 11:1118-24; PMID:16186818; http://dx.doi.org/10.1038/nm1292 50. International Conference on Harmonisation of Techni- cal Requirements for Registration of Pharmaceuticals for Human Use.,OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
Available from: http://www.ich.org/ﬁl eadmin/Public_Web_Site/ICH_Products/Guidelines/Efﬁcacy/E9/Step4/E9_Guideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6b/f3/khvi-11-07-1050570.PMC4514190.pdf
"© Terence L Kirley and Andrew B Norman *Correspondence to: Terence L Kirley; Email: terry.kirley@uc.eduSubmitted: 07/30/2014; Revised: 09/24/2014; Accepted: 10/04/2014 http://dx.doi.org/10.4161/21645515.2014.990856 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Anal Chem 2013; 85:715-36; PMID:23134362; http://dx.doi.org/ 10.1021/ac3032355 2.,OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
J Pharm Sci2008; 97:2426-47; PMID:17828757; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Biotechnol J 2011; 6:38-44; PMID: 20949542; http://dx.doi.org/10.1002/biot.,OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Methods Mol Biol 2013;988:305-17; PMID:23475728; http://dx.doi.org/ 10.1007/978-1-62703-327-5_19 5.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/ cwr027 6.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Pharm Res 2012; 29:187-97; PMID:21809161; http://dx.doi.org/10.1007/s11095-011-0534-2 7.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
J Pharm Sci 2009; 98:3117-30; PMID:19009595; http://dx.doi.org/10.1002/jps.21617 8.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Eur J Med Chem 2010; 45:2291-8; PMID:20185210; http://dx.doi.org/10.1016/j.ejmech.2010.02.004 9.,OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Nat Biotechnol 2005; 23:1117-25;PMID:16151405; http://dx.doi.org/10.1038/nbt113510.,OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
J Pharm Exp Ther 2007;320:145-53; PMID:17023573; http://dx.doi.org/ 10.1124/jpet.106.111781 11.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Drug Metab Dispos 2014; 42:1125-31; PMID:24733787; http://dx.doi.org/10.1124/dmd.114.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
J Pharm Sci 2007; 96:2607-21; PMID:17621682; http://dx.doi.org/10.1002/jps.20966 13.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
J Chromatogr A 2008; 1179:198-204;PMID:18096172; http://dx.doi.org/10.1016/j.chroma.,OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Anal Biochem 1989; 180:195-204; PMID:2510544; http://dx.doi.org/10.1016/0003-2697(89)90115-2 16.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
BMC Proc 2011; 5 Suppl 8:P110; http://dx.doi.org/10.1186/1753-6561-5-S8-P110 17.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
mAbs 2012; 4:17-23; PMID:22327427; http://dx.doi.org/10.4161/mabs.4.1.18347 18.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Methods 2000; 20:341-61; PMID:10694456; http://dx.doi.org/ 10.1006/meth.1999.0927 23.,OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Monoclon AntibImmunodiagn Immunother 2013; 32:262-4; PMID:23909419; http://dx.doi.org/10.1089/mab.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Anal Biochem 1989; 180:231-6; PMID:2554752;http://dx.doi.org/10.1016/0003-2697(89)90422-3 26.,OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Anal Chem 1985; 57:1931-7; PMID:4037347; http://dx.doi.org/ 10.1021/ac00286a032 27.,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
Cell 1977; 12:1133-41; PMID:23215; http://dx.doi.org/10.1016/0092-8674(77)90176-3 www.taylorandfrancis.com 467 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/ca/a7/khvi-11-02-990856.PMC4514192.pdf
"4,5CMV infection may also be transmitted from mother to fetus, congenital CMV (cCMV) © GlaxoSmithKline Biologicals SA *Correspondence to: Cosmina Hogea; Email: cosmina.s.hogea@gsk.comSubmitted: 05/28/2014; Revised: 01/20/2015; Accepted: 02/03/2015 http://dx.doi.org/10.1080/21645515.2015.1016665 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Rev Med Virol 2007; 17:253-76; PMID:17579921; http://dx.doi.org/10.1002/rmv.535 2.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
BMC Infect Dis 2007; 7:71; PMID:17605813;http://dx.doi.org/10.1186/1471-2334-7-71 3.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Semin Fetal Neonatal Med 2007; 12:154-9;PMID:17337260; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Cyto- megalovirus (CMV) and Congenital CMV Infection (http://www.cdc.gov/cmv/clinical/features.html).,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Scand J Infect Dis 2008;40:935-42; PMID:18720260; http://dx.doi.org/ 10.1080/00365540802308431 7.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
"Rev Med Virol 2010; 20:311-26;PMID:20645278; http://dx.doi.org/10.1002/rmv.659 8. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH, Vossen AC.",Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Rev Med Virol 2013; 23:241-9;PMID:23559569; http://dx.doi.org/10.1002/ rmv.1744 9.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
ClinInfect Dis 2010; 50:1439-47; PMID:20426575; http://dx.doi.org/10.1086/652438 11.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Clin Virol 2009; 46(Suppl 4):S6-10; PMID:19800841; http://dx.doi.org/10.1016/j.jcv.2009.09.002 12.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Clin Microbiol Rev 2013; 26:86-102; PMID:23297260; http://dx.doi.org/10.1128/ CMR.00062-12 13.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Pediatr Infect Dis J 1992; 11:93-9; PMID:1311066; http://dx.doi.org/ 10.1097/00006454-199202000-00007 14.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Rev Med Virol 2007; 17:355-63; PMID:17542052; http://dx.doi.org/10.1002/rmv.544 15.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Pediatr 2008; 153:84-8; PMID:18571542; http://dx.doi.org/10.1016/j.jpeds.2007.12.049 16.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
BMC Public Health 2005; 5:70; PMID:15967030; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
N Engl J Med 2009; 360:1191-9; PMID:19297572; http://dx.doi.org/10.1056/ NEJMoa0804749 19.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Vaccine 2013; 32:4-10; PMID:24129123; http://dx.doi.org/10.1016/j.vaccine.2013.09.042 20.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Vaccine 2013; 31(Suppl2):B197-203; PMID:23750795; PMID:23598482; http://dx.doi.org/10.1016/j.vaccine.2012.10.074 22.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Epi- demiol Infect 2011; 139:1818-26; PMID:21396147; http://dx.doi.org/10.1017/S0950268811000343 23.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Clin Infect Dis 2006; 43:1143-51; PMID:17029132; http://dx.doi.org/10.1086/508173 26.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Infect Dis 2010; 202:1800-3; PMID:21050121; http://dx.doi.org/10.1086/657412 28.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Exp Gerontol 2007; 42:563-70; PMID:17337145; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Ageing Res Rev 2011; 10:362-9; PMID:20727987; http://dx.doi.org/10.1016/j.arr.2010.08.003 30.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Curr Opin Immunol 2011;23:549-54; PMID:21664807; http://dx.doi.org/ 10.1016/j.coi.2011.05.002 31.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Rev Saude Publica 2001; 35:124-9; PMID:11359197; http://dx.doi.org/10.1590/ S0034-89102001000200004 32.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
United States Census Bureau (http://www.census.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Epide- miol Infect 2010; 138:802-12; PMID:19765352;http://dx.doi.org/10.1017/S0950268809990781 34.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Lancet Infect Dis 2012; 12:790-8; PMID:23017365; http://dx.doi.org/10.1016/S1473-3099(12)70197-4 35.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Lancet2009; 374:1975-85; PMID:19962185; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Conference Proceedings (http://www.systemdynamics.org/conferen ces/2010/proceed/papers/P1260.pdf).,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J R Soc Interface 2012; 9:2156-66; PMID:22491976; http://dx.doi.org/10.1098/rsif.2011.0891 39.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Epidemiol Infect 2009; 137:48- 57; PMID:18466660; http://dx.doi.org/10.1017/ S0950268808000563 40.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
Pediatr Rev 2007; 28:92-100; PMID:17332168;http://dx.doi.org/10.1542/pir.28-3-92 42.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Immunol 2004; 172:3260-7; PMID:14978134; http://dx.doi.org/ 10.4049/jimmunol.172.5.3260 www.tandfonline.com 1801 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Infect Dis 1999; 180:702-7; PMID:10438357; http://dx.doi.org/10.1086/314939 45.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Infect Dis 1989; 160:1-10; PMID:2543705; http://dx.doi.org/10.1093/infdis/160.1.1 46.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
PLoS Med 2008; 5:e74; PMID:18366252; http://dx.doi.org/ 10.1371/journal.pmed.005007447.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J R Stat Soc Ser C Appl Stat 2010;59:255-77; http://dx.doi.org/10.1111/j.1467- 9876.2009.00693.x 48.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
AmJ Epidemiol 2006; 164:936-44; PMID:16968863; http://dx.doi.org/10.1093/aje/kwj317 49.,Non-OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Pediatr 1987; 110:37-42;PMID:3025394; http://dx.doi.org/10.1016/S0022- 3476(87)80284-6 51.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
J Infect Dis 2010; 201:386-9;PMID:20039807; http://dx.doi.org/10.1086/649903 52.,OADS,/arxiv_data1/oa_pdf/3c/b6/khvi-11-07-1016665.PMC4514193.pdf
"Search Strategy A literature search was performed (on the 10th of March 2014) to identify articles analyzing the cost-effectiveness of© S Dirmesropian, JG Wood, CR MacIntyre, and AT Newall *Correspondence to: Anthony T Newall; Email: a.newall@unsw.edu.au Submitted: 09/01/2014; Revised: 11/13/2014; Accepted: 11/25/2014http://dx.doi.org/10.1080/21645515.2015.1011954 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
2013; Available from: http://www.who.int/ mediacentre/factsheets/fs178/en/ 2.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
2014; Available from: http://www.cdc.gov/pneumococcal/about/risk-transmis sion.html 3.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
CD000422; PMID:23440780; http://dx.doi.org/ 10.1002/14651858.CD000422.pub3 8.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Pediatr Infect Dis J2006; 25 6:494-501; PMID:16732146; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Clin Infect Dis 2012; 55 2:265-7;PMID:22495544; http://dx.doi.org/10.1093/cid/ cis364 10.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
PLoS ONE 2014; 9 4; PMID:24760002;http://dx.doi.org/10.1371/journal.pone.0094578 11.,OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Clin Infect Dis 2008; 46 7:1015-23; PMID:18444818; http://dx.doi.org/ 10.1086/529142 12.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Clin Infect Dis 2012; 55 5:e35-44; PMID:22652582; http://dx.doi.org/10.1093/cid/ cis513 13.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conju-gate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.Vaccine 2007; 25 20:4029-4037; PMID:17391816; http://dx.doi.org/10.1016/j.vaccine.2007.02.062 14.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Clin Infect Dis 2009; 49 9:1318-25; PMID:19814624; http://dx.doi.org/10.1086/606046 15.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Clin Infect Dis 2011; 526:736-42; PMID:21367726; http://dx.doi.org/ 10.1093/cid/cir003 16.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Vaccine 2010; 28 30:4763-70; PMID:20471437; http://dx.doi.org/10.1016/j.vaccine.2010.04.103 17.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Vaccine 2009; 27 10:1628-36; PMID:19100304; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
J Infect Dis 2008; 198 7:1019-27; PMID:18710324;http://dx.doi.org/10.1086/591629 20.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
FASEB J 2008; 22 2:338-42; PMID:17884971; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Am J Prev Med 2013; 44 4:373-81; PMID:23498103; http://dx.doi.org/10.1016/j.amepre.2012.11.035 25.,OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Vaccine 2012; 30 36:5437-44;PMID:22728289; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Vaccine2013; 31 37:3950-6; PMID:23806240; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
JAMA 2012; 307 8:804-12; PMID:22357831; http://dx.doi.org/10.1001/jama.2012.169 28.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Vaccine 2013; 31 50:6011-21; PMID:24148572; http://dx.doi.org/ 10.1016/j.vaccine.2013.10.024 29.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Hum VaccinImmunother 2013; 9 3:699-706; PMID:23295824; http://dx.doi.org/10.4161/hv.23268 30.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Hum Vaccin Immunother2014; 10 2:492-7; PMID:24185467; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Clin Ther 2010; 32 8:1517-32; PMID:20728764; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
BMC Infect Dis 2013; 13 1:175;PMID:23578307; http://dx.doi.org/10.1186/1471- 2334-13-175 34.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
"Med Decis Making, 2003; 23 1:76-82; PMID:12583457; http://dx.doi.org/10.1177/0272989X02239651 40.",Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
http://www.ahrq.gov/ data/hcup/41.,OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
"Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.Annal Internal Med, 2003; 138 12:960-8 CI42; PMID:12809452; http://dx.doi.org/10.7326/0003- 4819-138-12-200306170-00007 42.",Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
Vaccine 2002; 21 3-4:303-311; PMID:12450706; http://dx.doi.org/10.1016/S0264-410X(02)00451-6 43.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
294 16:2043-51; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043 44.,Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
"Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination.Lancet 2011; 378 9807:1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8 www.taylorandfrancis.com 825 Human Vaccines & Immunotherapeutics",Non-OADS,/arxiv_data1/oa_pdf/ff/66/khvi-11-04-1011954.PMC4514194.pdf
"Vaccine efﬁcacy (VE) was © Raul Isturiz and Chris Webber *Correspondence to: Raul Isturiz; Email: Raul.Isturiz@p ﬁzer.com Submitted: 04/01/2015; Accepted: 04/15/2015 http://dx.doi.org/10.1080/21645515.2015.1043502 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
N Engl J Med 2015; 372: 1114-25;PMID:25785969; http://dx.doi.org/10.1056/NEJMoa 1408544 2.,OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Vaccine 2014; 32: 2364-74; PMID:24606865; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Vaccine 2011; 29: 5195-202; PMID:21619909; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Pediatr Infect Dis J 2012; 31: 297-301; PMID:22330166; http://dx.doi.org/ 10.1097/INF.0b013e318247ef847.,OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Clin Infect Dis 2014; 59:1066-3; PMID:25034421; http://dx.doi.org/10.1093/ cid/ciu524 8.,Non-OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Lancet Infect Dis 2015; 15:301-9; [Epub ahead of print]; PMID:25656600; http://dx.doi.org/ 10.1016/S1473-3099(14)71081-3 9.,Non-OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
J Infect Dis 2010; 201: 32-41; PMID:19947881; http://dx.doi.org/10.1086/648593 10.,OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Thorax 2012; 67: 540-5;PMID:22374921; http://dx.doi.org/10.1136/thoraxjnl- 2011-201092 11.,Non-OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
J Infect Dis 2013; 208: 1813-20; PMID:24092845; http://dx.doi.org/10.1093/infdis/ jit506 12.,OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Int J Infect Dis 2014; 33: 22-7;PMID:25541296; http://dx.doi.org/10.1016/j.ijid.,OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Pediatr Infect Dis J 2013; 32: 203-7;PMID:23558320; http://dx.doi.org/10.1097/INF.,OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
Vaccine 2013; 31: 6232-8; PMID:24176490; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/78/38/khvi-11-07-1043502.PMC4514202.pdf
"The Na-APR-1 protein is expressed in the gut of the adult N. americanus parasites where it functions in concert with the cysteine protease Na-CP-3 and the metalloprotease Na-MEP-1 to digest the hemoglobin tetramer.7–9Due to its role © Christopher A Seid, Elena Curti, R Mark Jones, Elissa Hudspeth, Wanderson Rezende, Jeroen Pollet, Lori Center, Leroy Versteeg, Sonya Pritchard, Ko nstantin Musiychuk, Vidadi Yusibov, Peter J Hotez, and Maria Elena Bottazzi*Correspondence to: Maria Elena Bottazzi; Email: bottazzi@bcm.eduSubmitted: 12/17/2014; Revised: 03/13/2015; Accepted: 03/27/2015 http://dx.doi.org/10.1080/21645515.2015.1036207 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
PLoS Negl Trop Dis 2014; 8:e2865; PMID:25058013; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Parasit Vectors 2014; 7:37; PMID:24447578; http://dx.doi.org/10.1186/1756-3305-7-37 3.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
N Engl J Med 2004; 351:799–807; PMID:15317893; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Blood 2014; 123:615–24; PMID:24297872; http://dx.doi.org/ 10.1182/blood-2013-06-508325 5.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Trop Med Int Health 2010; 15:776–95; http://dx.doi.org/10.1111/j.1365-3156.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
PLoS Negl Trop Dis 2008; 2:e291; PMID:18820740;http://dx.doi.org/10.1371/journal.pntd.0000291 7.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
J Infect Dis2009; 199:904–12; PMID:19434933; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Trends Parasitol 2003; 19:417–23; PMID:12957519; http://dx.doi.org/10.1016/S1471-4922(03)00189-2 9.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
FASEB J 2009; 23:3007–19; PMID:19380510; http://dx.doi.org/10.1096/fj.09-131433 10.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
PLoS Med 2005; 2:e295;PMID:16231975; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Exp Parasitol 2008; 118:32–40; PMID:17645877; http://dx.doi.org/10.1016/j.exppara.2007.05.010 12.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Infect Immun 2005; 73:6903– 11; PMID:16177370; http://dx.doi.org/10.1128/ IAI.73.10.6903-6911.2005 13.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Infect Immun 2010; 78:1552–63; PMID:20145100; http://dx.doi.org/10.1128/IAI.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Protein Exp Purif 2012; 83:145–51; PMID:22503665; http://dx.doi.org/10.1016/j.pep.2012.03.013 16.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Biologicals 2008; 36:354–8; PMID:18938088; http://dx.doi.org/10.1016/j.biologicals.2008.09.001 19.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Plant Biotechnol J 2010; 8:620–37; PMID:20233333; http://dx.doi.org/10.1111/j.1467- 7652.2010.00507.x 20.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Curr Opin Biotechnol 2001; 12:450–4; PMID:11604319; http://dx.doi.org/10.1016/S0958-1669(00)00244-5 21.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Vaccine 2007; 25:3014–7; PMID:17287055; http://dx.doi.org/ 10.1016/j.vaccine.2007.01.017 22.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Vaccine 2008; 26:2930–4;PMID:18440103; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Inﬂuenza other Respir viruses 2007; 1:19–25; PMID:19453476; http://dx.doi.org/10.1111/j.1750-2659.2006.00005.x 24.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Vaccine 2009; 27:1087–92; PMID:19100806; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Plant Physiol 1987; 85:942–6; PMID:16665835;http://dx.doi.org/10.1104/pp.85.4.942 26.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Biotechnol J 2009; 4:230–7; PMID:19156736; http://dx.doi.org/10.1002/biot.200800256 27.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Vaccine 2009; 27:6054–9; PMID:19660590; http://dx.doi.org/10.1016/j.vaccine.2009.07.067 28.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Human Vaccines 2011; 7(3): 313–21; PMID:21346417; http://dx.doi.org/10.4161/hv.7.3.14207 31.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
"Lai H, Chen Q. Bioprocessing of plant-derived virus- like particles of Norwalk virus capsid protein under current Good Manufacturing Practice regulations.Plant Cell Rep. 2012 31:573–584; PMID:22134876; http://dx.doi.org/10.1007/s00299-011-1196-6 34.",OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
Biotechnology Advances 2012 30: 434–439; PMID:21856403; http://dx.doi.org/ 10.1016/j.biotechadv.2011.08.007 35.,OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
2012 17(6) 449–457; PMID:23015521; http://dx.doi.org/10.1177/2211068212460037 36.,Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
"FDA, Rockville MD; 2002; 2–20; http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/Guidance forindustry/UCM055424.pdf 1488 Volume 11 Issue 6 Human Vaccines & Immunotherapeutics",Non-OADS,/arxiv_data1/oa_pdf/62/e9/khvi-11-06-1036207.PMC4514214.pdf
"A second dose given 4–12 wk after primary immunization elicits comparable antibody  *Correspondence to: Paolo Bonanni; Email address: paolo.bonanni@unifi.it Submitted: 07/03/2014; Accepted: 07/10/2014; Published Online: 08/06/2014http://dx.doi.org/10.4161/hv.34311Impact of universal vaccination   against varicella in Italy Experiences from eight Italian Regions an gela Bechini1, sa ra Boccalini1, Vincenzo Baldo2, si lvia co cchio2, Paolo ca stiglia3, Tolinda Gallo4, sa ndro Giuffrida5, Francesco  Locuratolo6, si lvio Tafuri7, Domenico Martinelli8, Rosa Prato8, em anuele am odio9, Francesco Vitale9, and Paolo Bonanni1,* 1Department of he alth sc iences; University of Florence; Florence, Italy; 2Department of Molecular Medicine; Public he alth se ction, University of Padua; Padua, Italy;  3Department of Biomedical sc iences; University of sa ssari; sa ssari, Italy; 4Local he alth Unit 4 Medio Friuli; Friuli Venezia Giulia, Italy; 5Local he alth Unit; Reggio calab ria, Italy;  6Department of he alth, sa fety and so cial so lidarity; Basilicata Region; Potenza, Italy; 7Department of Biomedical sc iences and hu man Oncology; University of Bari al do  Moro; Bari, Italy; 8Department of Medical and su rgical sc iences; University of Foggia; Foggia, Italy; 9Department of sc iences for he alth Promotion and Mother to child care “G.",Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Lancet 1993; 341:308-9; PMID:8093945 ;  http://dx.doi.org/10.1016/0140-6736(93)92663-E 2.,OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Lancet 2006;  368:1365-76;  PMID:17046469 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Pediatr Infect Dis J 2013; 32:e305-13; PMID:23838789 ;  http://dx.doi.org/10.1097/INF.0b013e31828b7def8.,OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
J Infect Dis 1996; 174(Suppl 3):S310-3; PMID:8896537 ; http://dx.doi.org/10.1093/ infdis/174.Supplement_3.S310 9.,OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Italian Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_948_allegato.pdf 11.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Italian Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_543_allegato.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Italian Available from: http://www.salute.gov.it/imgs/c_17_pubblicazioni_1721_allegato.pdf 13.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Available from: http://demo.istat.it/ .,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Epidemiol Infect 2002; 128:479-84;  PMID:12113493 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Health Policy 2011; 103:176-83;  PMID:22030308 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
BMC Infect Dis 2009; 9:150; PMID:19737419 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Available from: http://www.agenziafarmaco.gov.,Non-OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
Curr Med Res Opin 2007; 23:2945-54;  PMID:17937842 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/42/12/khvi-11-01-984111.PMC4514224.pdf
"Correspondence to Edouard Kurstak, Email: icwo@sympatico.ca Submitted: 07/31/2014 ; Accepted: 07/31/2014 ; Published Online: 09/05/2014 http://dx.doi.org/10.4161/hv.36386Ninth World Congress on Vaccines, Immunisation  and Immunotherapy edouard  Kurstak Infections c ontrol World Organization; f aculty of Medicine; University of Montreal; Montreal, Q c canada",Non-OADS,/arxiv_data1/oa_pdf/28/fa/khvi-11-01-984101.PMC4514226.pdf
"© Silvio Tafuri, Maria Serena Gallone, Maria Filomena Gallone, Maria Giovanna Cappelli, Maria Chironna, and Cinzia Germinario *Correspondence to: Silvio Tafuri; Email: silvio.tafuri@uniba.it Submitted: 12/12/2014 Accepted: 12/25/2014 http://dx.doi.org/10.1080/21645515.2015.1009818 This is an Open Access article distributed under theterms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Epidemiol Infect 1995; 115:139- 56; PMID:7641827; http://dx.doi.org/10.1017/S0950268800058209 3.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Am J Epidemiol 2004 Apr 15; 159(8):786-94; http://dx.doi.org/10.1093/aje/kwh107 4.,OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Hum Vaccin 2011 Sep; 7(9):900-4; http://dx.doi.org/ 10.4161/hv.7.9.16084 8.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Scand J Infect Dis 1996; 28:31-35; PMID:9122630; http://dx.doi.org/10.3109/ 00365549609027146 10.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
BMC Infect Dis 2008 Oct 30; 8:150; http://dx.doi.org/10.1186/1471-2334-8-150 11.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
J Hyg Camb 1985;94:365- 435; PMID:4008922; http://dx.doi.org/10.1017/ S002217240006160X www.taylorandfrancis.com 899 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
J Hyg Camb 1986; 96:305-33;PMID:3701044; http://dx.doi.org/10.1017/ S0022172400066079 13.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Vaccine 2000 Apr14; 18(20):2073-4; http://dx.doi.org/10.1016/S0264- 410X(99)00557-5 14.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Br Med Bull 2012; 103:115-12; http://dx.doi.org/10.1093/bmb/lds01919.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
BMC InfecDis 2013; 13:303; PMID:23815523; http://dx.doi.org/ 10.1186/1471-2334-13-303 20.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Available from: http://venice.cineca.org/report_ﬁnal_varicella.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Epidemiol Infect 2003;131:1085-9; PMID:14959774; http://dx.doi.org/ 10.1017/S0950268803001134 24.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Vaccine 2007 Nov 7; 25(45):7866- 72; http://dx.doi.org/10.1016/j.vaccine.2007.07.036 26.,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Vaccine 2011 Mar 16; 29(13):2411-20; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
Vaccine 2010 Apr 26; 28(19):3385-97; http://dx.doi.org/10.1016/j.vaccine.2010.02.079 900 Volume 11 Issue 4 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/0d/4e/khvi-11-04-1009818.PMC4514230.pdf
"Several immunotherapy candidates failed to show efﬁcacy in humans:Altastaph (Nabi Biopharmaceuticals) containing S.aureus capsular © Ali Fattom, Albert Matalon, John Buerkert, Kimberly Taylor, Silvia Damaso, and Dominique Boutriau *Correspondence to: D Boutriau; Email: dominique.boutriau@gsk.comSubmitted: 05/21/2014; Revised: 07/30/2014; Accepted: 08/11/2014 http://dx.doi.org/10.4161/hv.34414 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Infect Control Hosp Epidemiol 2013; 34:1-14; PMID:23221186; http://dx.doi.org/10.1086/668770 2.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Clin J Am Soc Nephrol 2009; 4:1388-400; PMID:19590063; http://dx.doi.org/10.2215/CJN.015903093.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Clin J Am Soc Nephrol 2008; 3:1526-33; PMID:18701615; http://dx.doi.org/10.2215/CJN.,OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
J Am Soc Nephrol 2012; 23:1551-9; PMID:22904350;http://dx.doi.org/10.1681/ASN.2012010050 5.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Clin J Am Soc Nephrol 2009; 4:428-34;PMID:19118117; http://dx.doi.org/10.2215/CJN 03760708.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Clin J Am Soc Nephrol 2008; 3:1726-32; PMID:18922993; http://dx.doi.org/ 10.2215/CJN.01240308 9.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Nephron Clin Pract 2012; 120 (Suppl 1):c233-45; PMID:22964570; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Infect Dis Clin North Am 2009; 23:153-71; PMID:19135920; http://dx.doi.org/ 10.1016/j.idc.2008.10.005 12.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Vaccine 2012; 30:2921-7;PMID:22115633; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
JAMA 2013; 309:1368-78; PMID:23549582; http://dx.doi.org/10.1001/jama.2013.3010 14.,OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Clin Microbiol Rev 2004; 17:218-34;PMID:14726462; http://dx.doi.org/10.1128/ CMR.17.1.218-234.2004 15.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Diagn Microbiol Infect Dis 2007; 58:297-302; PMID:17376630; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
J Clin Microbiol 2007; 45:725-9; PMID:17202275; http://dx.doi.org/10.1128/JCM.01572-06 18.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
N Engl J Med 2002; 346:491-6; PMID:11844850; http://dx.doi.org/ 10.1056/NEJMoa011297 19.,OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
FEMS Immunol Med Microbiol 2011; 63:16-24; PMID:21631600; http://dx.doi.org/10.1111/j.1574-695X.2011.00822.x 20.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Semin Dial 2007; 20:440-51; PMID:17897251; http://dx.doi.org/10.1111/j.1525- 139X.2007.00283.x 21.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
J Am Soc Nephrol 2008; 19:1483-90; PMID:18480314; http://dx.doi.org/10.1681/ASN.2007090971 22.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Nephrol Dial Transplant 2010; 25:737-46; PMID:19903659; http://dx.doi.org/ 10.1093/ndt/gfp580 23.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Vaccine 2009; 28:256-60; PMID:19799842; http://dx.doi.org/10.1016/j.vaccine.2009.09.088 24.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Infect Immun 2005; 73:3502-11;PMID:15908379; http://dx.doi.org/10.1128/IAI.73.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Expert Opin Ther Targets 2012; 16:601-12; PMID:22530584; http://dx.doi.org/ 10.1517/14728222.2012.682573 27.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
PLoS ONE 2009; 4:e5446; PMID:19424507; http://dx.doi.org/ 10.1371/journal.pone.0005446 28.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Clin Infect Dis 2012; 54:560-7; PMID:22186773; http://dx.doi.org/10.1093/cid/cir828 29.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
PLoS Pathog 2009; 5: e1000703; PMID:20041174; http://dx.doi.org/ 10.1371/journal.ppat.1000703 30.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Infect Immun 2008;76:4574-80; PMID:18644876; http://dx.doi.org/ 10.1128/IAI.00700-08 31.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Curr Opin Microbiol 2012; 15:92-9; PMID:22088393; http://dx.doi.org/10.1016/ j.mib.2011.10.012 33.,OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
Vaccine 2004; 23:656- 63; PMID:15542186; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/7e/a2/khvi-11-03-977202.PMC4514248.pdf
"The Sanoﬁ-Connaught brandincludes Tripedia /C210, which was licensed by Connaught in 1992 © Cristina Masseria, Ami R Buikema, Fang Liu, and Girishanthy Krishnarajah *Correspondence to: Cristina Masseria; Email: Cristina.Masseria@p ﬁzer.com Submitted: 04/25/2014; Revised: 10/10/2014; Accepted: 10/22/2014 http://dx.doi.org/10.4161/21645515.2014.985506 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Avail- able from: http://www.heal thychildren.org/English/ health-issues/vaccine-preventable-diseases/pages/Whooping-Cough-(Pertussis).aspx.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Br Med J 2010; 341:c4627; http://dx.doi.org/ 10.1136/bmj.c4627 9.,OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
N Engl J Med 2012;367:785-7; PMID:22894554; http://dx.doi.org/ 10.1056/NEJMp1209051 10.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Pediatrics 2003; 112:405-6; PMID:12897292; http://dx.doi.org/10.1542/peds.112.2.405 11.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Am J Epidemiol 2005; 161:1159-67; PMID:15937025; http://dx.doi.org/10.1093/aje/kwi141 12.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: https://www.vac cineshoppe.com/image.cfm?doc_id=11179&image_ty pe=product_pdf.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.fda.gov/ downloads/BiologicsBloodVaccines/Vaccines/Appro vedProducts/UCM101580.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM109841.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.fda.gov/downloads/BiologicsBlood Vaccines/Vaccine s/ApprovedProducts/UCM241874.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.fda.gov/downloads/Biologi csBloodVaccines/Vaccine s/ApprovedProducts/ UCM109810.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vac cines/ApprovedProducts/UCM241453.pdf.,OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Pediatrics 2002;109:666-72; PMID:11927713; http://dx.doi.org/ 10.1542/peds.109.4.666 24.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
PediatrInfect Dis J 2000; 19:757-59; PMID:10959748; http://dx.doi.org/10.1097/00006454-200008000- 00018 25.,OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Am J Publ Health 2006; 96:691-6; http://dx.doi.org/ 10.2105/AJPH.2004.053306 27.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.ncqa.org/Portals/0/State%20of%20Health%20Care/2012/SOHC%20Report%20Web.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Publ Health Rep 2000; 115:65-77; http://dx.doi.org/10.1093/phr/115.1.65 29.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.cms.hhs.gov/HIPAAGenInfo/Down loads/HIPAALaw.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
Available from: http://www.vaccines.mil/documents/1398SanoﬁPas teur_Trpedia_TriHIBitLtr.pdf.,OADS,/arxiv_data1/oa_pdf/8d/b6/khvi-11-05-985506.PMC4514255.pdf
"However, following the discontinuation of W1883 production by the manufacturer (West), the syringe presenta-tion has recently been replaced using preﬁlled syringes from adifferent manufacturer, wherein the tip-cap component con-tains FM27 (a latex-free non-cytotoxic rubber compound) and © Noris Pavia-Ruz, Katia Abarca, Alejandro Lepetic, Maria Yolanda Cervantes-Apolinar, Karin Hardt, Girish Jayadeva, Sherine Kuriyakose, Htay Hta y Han, and Manuel de la O*Correspondence to: Htay Htay Han; Email: Htay.H.Han@gsk.comSubmitted: 01/14/2015; Revised: 03/30/2015; Accepted: 04/13/2015 http://dx.doi.org/10.1080/21645515.2015.1041697 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Int J Environ Res Public Health 2012; 9:4626-38; PMID:23330226; http://dx.doi.org/10.3390/ijerph9124626 2.,OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Vaccine 2011; 29:1115-21; PMID:21168525; http://dx.doi.org/ 10.1016/j.vaccine.2010.12.010 3.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Pediatr Infect Dis J 2005; 24: S58-61; PMID:15876927; http://dx.doi.org/10.1097/ 01.inf.0000160914.59160.41 4.,OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Drugs 2012; 72:1765- 91; PMID:22931522; http://dx.doi.org/10.2165/ 11209630-000000000-00000 5.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
BioDrugs 2013; 27:75-81; PMID:23329401; http://dx.doi.org/10.1007/s40259-012-0009-y 6.,OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Vaccine 2011;29:5932-9; PMID:21718738; http://dx.doi.org/ 10.1016/j.vaccine.2011.06.0498.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Vaccine 2012; 30:1721-8; PMID:22212127; http://dx.doi.org/10.1016/j.vaccine.2011.12.055 9.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Rev Med Chile 2002; 130:502-10; PMID:12143270; http://dx.doi.org/10.4067/S0034- 98872002000500004 10.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
J Adolesc Health 2005;37:517; PMID:16310132; http://dx.doi.org/10.1016/ j.jadohealth.2005.08.009 12.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Pediatrics 2006; 117:1084-93; PMID:16585302; http://dx.doi.org/10.1542/peds.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Vaccine 2010; 29:45-50;PMID:20974302; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Vaccine 2009; 27:765-72; PMID:19041352; http://dx.doi.org/ 10.1016/j.vaccine.2008.11.028 16.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Vaccine2007; 25:5248-52; PMID:17583395; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Eur J Pediatr 2005; 164:377-82; PMID:15782295; http://dx.doi.org/10.1007/s00431-005-1650-y 19.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Human vaccines 2009; 5:858-66; PMID:19838080; http://dx.doi.org/10.4161/hv.9961 20.,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
Eur J Pediatr 2007; 166:1229-36; PMID:17235521; http://dx.doi.org/10.1007/s00431- 006-0403-x 1774 Volume 11 Issue 7 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/56/eb/khvi-11-07-1041697.PMC4514261.pdf
"13 Many, but  not all papillomaviruses encode E5 proteins and the E5 ORF is often deleted in cervical carcinoma cells indicating that it may not  *Correspondence to: Aldo Venuti; Email: venuti@ifo.it Submitted: 06/23/2014; Accepted: 06/30/2014; Published Online: 08/06/2014 http://dx.doi.org/10.4161/hv.34303Anti-tumor effects of genetic vaccines against HPV  major oncogenes Marcelo Nazário co rdeiro1,†, Francesca Paolini2,†, si lvia Massa3, Gianfranca cu rzio2, el ena Illiano4, an na Jéssica Duarte si lva1,  Rosella Franconi3, Massimiliano Bissa4, ca rlo De Giuli Morghen4, an tonio ca rlos de Freitas1, and aldo  Venuti2,* 1Federal University of Pernambuco; Department of Genetics; Laboratory of Molecular st udies and ex perimental Therapy (L eM Te) ; Pernambuco, Brazil; 2Regina el ena National  ca ncer Institute; Laboratory of Virology –  hP V-UNIT; Rome, Italy; 3eNea;  Italian National age ncy for New Technologies, en ergy and su stainable ec onomic Development; c. R.  ca saccia, UT BIOR aD -FaR M; Rome, Italy; 4Department of Medical Biotechnologies and Translational Medicine; Università di Milano; Milan, Italy †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Int J Cancer 2012; 131:2349-59;  PMID:22323075 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
"Vaccine 2006; 24(Suppl 3):S3, 52-61;  PMID:16950018 ; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Nat Rev Cancer 2002; 2:342-50; PMID:12044010 ;  http://dx.doi.org/10.1038/nrc798 4.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Virology 2013; 445:224-31;  PMID:23928291 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Virology 2009; 384:260-5;  PMID:19135222 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Natl Cancer Inst 2000; 92:709-20;  PMID:10793107 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Natl Cancer Inst 2003; 95:1772-83; PMID:14652239 ; http://dx.doi.org/10.1093/jnci/ djg107 9.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Mol Carcinog 2000; 28:42-50; PMID:10820487 ; http://dx.doi.org/10.1002/ (SICI)1098-2744(200005)28:1<42::AID-MC6>3.0.CO;2-8 10.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Gen Virol 2010; 91:521-30; PMID:19812262 ; http://dx.doi.org/10.1099/ vir.0.016295-0 11.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Proc Natl Acad Sci U S A 2012; 109:E260-7;  PMID:22232672 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Biochem Pharmacol 2010; 80:1930-5; PMID:20643111 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Oncogene 2001; 20:7866-73;  PMID:11753669 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Oncogene 2000; 19:3727-32; PMID:10949926 ; http://dx.doi.org/10.1038/ sj.onc.1203718 18.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Int J Cancer 2006; 119:2105-12;  PMID:16823848 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Clin Invest 2001; 108:669-78;  PMID:11544272 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Virol 2004; 78:8468-76; PMID:15280455 ; http://dx.doi.org/10.1128/ JVI.78.16.8468-8476.2004 22.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol 2010 ; 17:1576-83 ;  PMID:20739505 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Virol 2000; 74:9083-9; PMID:10982354 ; http://dx.doi.org/10.1128/ JVI.74.19.9083-9089.2000 25.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Int J Cancer 2008; 122:247-59; PMID:17973257 ; http://dx.doi.org/10.1002/ ijc.23252 26.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Eur J Immunol 1993; 23:2242-9;  PMID:7690326 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Hum Gene Ther 2008; 19:354-64; PMID:18439124 ;  http://dx.doi.org/10.1089/hum.2007.122 28.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Hum Vaccin 2011; 7(Suppl):147-55; PMID:21266841 ; http://dx.doi.org/10.4161/ hv.7.0.14577 29.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Virol 2004; 78:1333-43;  PMID:14722288 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Virology 2001; 281:231-8;  PMID:11277695 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Vaccine 2003; 21:1125-36; PMID:12559790 ;  http://dx.doi.org/10.1016/S0264-410X(02)00519-4 33.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Vaccine 2007; 25:3018-21; PMID:17280752 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Virology 2003; 311:105-14;  PMID:12832208 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Arch Virol 2000; 145:2183-91; PMID:11087100 ; http://dx.doi.org/10.1007/ s007050070048 37.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Virol 2012; 86:5341-51;  PMID:22357280 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Protein Expr Purif 2003; 30:1-10; PMID :12821315 ;  http://dx.doi.org/10.1016/S1046-5928(03)00049-4 39.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Mol Med (Berl) 2013; 91:1221-31; PMID :23715898 ; http://dx.doi.org/10.1007/ s00109-013-1054-940.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Immunol Res 2010; 47:86-112;  PMID:20066511 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Exp Clin Cancer Res 2014; 33:29; PMID:24667138 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Oncogene 2009; 28:762-72;  PMID:19015633 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
J Immunol Methods 1995; 181:45-54;  PMID:7537312 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
Vaccine 2009; 27:5906-12;  PMID:19651174 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/45/khvi-11-01-984108.PMC4514265.pdf
"com Submitted: 02/09/2015; Revised: 04/02/2015; Accepted: 04/17/2015http://dx.doi.org/10.1080/21645515.2015.1043501 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
JAMA JAm Med Assoc 1996; 276:1869-72; http://dx.doi.org/ 10.1001/jama.1996.03540230019013 3.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Risk Anal Off Publ Soc Risk Anal 2014;34:541-55; http://dx.doi.org/10.1111/risa.12114 5.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
; [cited 2014 Nov 21]; Available from:https://www.gov.uk/government/publications/whoop ing-cough-pertussis-statistics 7.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Expert Rev Vaccines 2007; 6:723-39; PMID:17931153; http://dx.doi.org/ 10.1586/14760584.6.5.723 11.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Nat Rev Immunol 2009; 9:287-93; PMID:19247370;http://dx.doi.org/10.1038/nri2510 12.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Expert Rev Vaccines 2013; 12:747-58; PMID:23885820; http://dx.doi.org/10.1586/14760584.2013.811188 13.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Expert Rev Vaccines 2013; 12:779- 91; PMID:23885823; http://dx.doi.org/10.1586/ 14760584.2013.811195 14.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Expert Rev Vaccines 2012; 11:349-66; PMID:22380826; http://dx.doi.org/10.1586/erv.11.192 15.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2010; 28:4719-30; PMID:20451636; http://dx.doi.org/10.1016/j.vaccine.2010.04.07017.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
"Angelo M-G, Taylor S, Struyf F, Tavares Da Silva F, Arellano F, David M-P, Dubin G, Rosillon D, Baril L. Strategies for continuous evaluation of the beneﬁt-risk proﬁle of HPV-16/18-AS04-adjuvanted vaccine.Expert Rev Vacc 2014; 13:1297-306; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Curr Opin Infect Dis 2011; 24:190-5;PMID:21415741; http://dx.doi.org/10.1097/ QCO.0b013e328345d563 20.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
J Pathol 2007; 211:144-56; PMID:17200946; http://dx.doi.org/10.1002/path.2104 22.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Immunol Lett 2014; 162:41-8; http://dx.doi.org/10.1016/j.imlet.2014.06.013 23.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Arch Dis Child 2004; 89:751-6; PMID:15269077;http://dx.doi.org/10.1136/adc.2003.028449 24.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
JAMA Pediatr 2013; 167:1111-7; PMID:24126936; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
J Infect Dis 2014; 209 3:S114-9; PMID:24966191; http://dx.doi.org/10.1093/infdis/jiu066 26.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Expert Rev Vaccines 2014; 13:399-415; PMID:24512188; http://dx.doi.org/10.1586/14760584.2014.883285 27.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Arch Pediatr Adolesc Med 1997;151:255-9; PMID:9080932; http://dx.doi.org/ 10.1001/archpedi.1997.02170400041007 28.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Available from: http://www.fda.gov/downloads/BiologicsBlood Vaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM175909.pdf 29.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/S cientiﬁc_guideline/2009/ 09/WC500003870.pdf 30.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
2012; [cited 2014 Jul 28]; Available from: http://www.fda.gov/downloads/EmergencyPreparedness/Medical Countermeasures/UCM292045.pdf 32.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
; [cited 2014 Oct 6]; Available from: http://www.fda.gov/ Safety/SafetyofSpeciﬁcProducts/ucm180580.htm 33.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/ 10.1016/j.immuni.2010.10.002 34.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2010; 28 3:C25-36; PMID:20713254; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
WHO; [cited 2012 Apr 1]; Available from: http://www.who.int/csr/resources/publi cations/inﬂuenza/WHO_CDS_EPR_GIP_2006_1/en/index.html 36.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
BMC Infect Dis 2013;13:435; PMID:24041010; http://dx.doi.org/10.1186/ 1471-2334-13-435 37.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Expert Rev Vaccines 2011; 10:539-50; PMID:21506650; http://dx.doi.org/10.1586/ erv.11.21 38.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Expert Rev Vaccines 2013; 12:733-46; PMID:23885819; http://dx.doi.org/10.1586/ 14760584.2013.811185 39.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Nat Rev Microbiol 2007; 5:505-17; PMID:17558426; http://dx.doi.org/10.1038/ nrmicro1681 40.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Philos Ethics Humanit Med PEHM 2009; 4:2; http://dx.doi.org/10.1186/1747- 5341-4-2 41.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Available from: http://www.ema.eur opa.eu/docs/ en_GB/docu ment_library/Scientiﬁc_guideline/2009/10/ WC500004004.pdf 42. WHO.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Available from: http://www.who.int/biologicals/areas/vaccines/ADJUVANTS_Post_ECBS_edited_ clean_Guidelines_NCE_Adjuvant_Final_17122013_ WEB.pdf 43.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2011; 29:4453-9;PMID:21527299; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Clin Trials Lond Engl 2009; 6:430-40; http://dx.doi.org/10.1177/1740774509344101 48.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/NEJMoa052434 50.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2009; 28:345-51; PMID:19879226; http://dx.doi.org/10.1016/j.vaccine.2009.10.041 51.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
[cited 2015 Jan 6]; Available from: http://www.cdc.gov/vaccinesafety/vaccines/rotavsb.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2002; 21:298-302; PMID:12450705; http://dx.doi.org/10.1016/S0264-410X(02)00449-8 53.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2008; 26:6349-60;PMID:18805456; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Nat Rev Immunol 2006; 6:823- 35; PMID:17063184; http://dx.doi.org/10.1038/ nri1957 56.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2013; 31:1870-6; PMID:23391600; http://dx.doi.org/10.1016/j.vaccine.2013.01.042 57.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Ann Neurol 2011; 70:410-7;PMID:21866560; http://dx.doi.org/10.1002/ ana.22587 59.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Hum Vaccines Immunother 2014; 10:572-6; http://dx.doi.org/10.4161/hv.27412 61.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2013; 31:4448-58; PMID:23770307; http://dx.doi.org/10.1016/j.vaccine.2013.06.032 65.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine2012; 30:7123-9; PMID:23022149; http://dx.doi.org/ 10.1016/j.vaccine.2012.09.032 66.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
PloS One 2014; 9:e82222; PMID:24404128; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Arch Dis Child 2001; 84:227-9; PMID:11207170; http://dx.doi.org/10.1136/ adc.84.3.227 68.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Eur J Intern Med 2010; 21:70-3; PMID:20206873; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
WHO; [cited 2014 Mar 20]; Available from:http://www.who.int/vaccine_safety/committee/topics/ aluminium/statement_112002/en/ 71.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Lancet 2003; 362:1659-66; PMID:14630450; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
J Allergy Clin Immunol 2007; 120:506-15;PMID:17765751; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Brain J Neurol 2006; 129:1953-71; http://dx.doi.org/ 10.1093/brain/awl075 74.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Lancet Infect Dis 2009; 9:418-27; PMID:19555901; http://dx.doi.org/ 10.1016/S1473-3099(09)70132-X 76.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Pharmacoepidemiol Drug Saf 2014; 23:456-65; PMID:24644078; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
Vaccine 2008; 26:6630-8;PMID:18845199; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/18/30/khvi-11-07-1043501.PMC4514270.pdf
"RiVax, which © Tao Zhang, Hao Yang, Lin Kang, Shan Gao, Wenwen Xin, Wenwu Yao, Xiangjin Zhuang, Bin Ji, and Jinglin Wang *Correspondence to: Jinglin Wang; Email: wjl0801@vip.163.comSubmitted: 01/29/2015; Revised: 03/15/2015; Accepted: 04/02/2015 http://dx.doi.org/10.1080/21645515.2015.1038446 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
J Gastroenterol Hepatol2010; 25:1266-75; PMID:20594254; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Toxicol Ind Health 2012; 28:439-48; PMID:21937530; http://dx.doi.org/10.1177/0748233711414608 6.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Toxicol Rev 2003; 22: 53-64; PMID:14579547; http://dx.doi.org/10.2165/ 00139709-200322010-00006 7.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
JAMA 2005;294:2342-51; PMID:16278363; http://dx.doi.org/ 10.1001/jama.294.18.2342 8.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Vaccine 2002; 20:1681-91; PMID:11858879; http://dx.doi.org/10.1016/S0264- 410X(01)00484-4 9.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Vaccine 1996; 14:1031-8; PMID:8879098; http://dx.doi.org/10.1016/0264-410X(96)00063-1 10.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Vaccine 1998; 16:530-5;PMID:9491508; http://dx.doi.org/10.1016/S0264- 410X(97)80007-2 11.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Vaccine 2007; 25:7459-69; PMID:17875350; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Vaccine 2010; 28:5315-22; PMID:20562013; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Vaccine 2002;20:3422-7; PMID:12213413; http://dx.doi.org/ 10.1016/S0264-410X(02)00312-2 17.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Proc Natl Acad Sci U S A 2006; 103:2268-73; PMID:16461456; http://dx.doi.org/10.1073/ pnas.0510893103 18.,OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Clin Vaccine Immunol 2012; 19:1697-9;PMID:22914366; http://dx.doi.org/10.1128/ CVI.00381-12 19.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Toxicol Sci 2012; 126:72-83;PMID:21987460; http://dx.doi.org/10.1093/toxsci/ kfr274 20.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
17:391-7; PMID:15187223; http://dx.doi.org/ 10.1093/protein/gzh043 22.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Int J Toxicol 2011; 30:143-52; PMID:21378370; http://dx.doi.org/10.1177/1091581810396730 23.,OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Protein Sci 2004;13:2736-43; PMID:15340172; http://dx.doi.org/ 10.1110/ps.04897904 24.,OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Expert Rev Vaccines 2005; 4:229-37;PMID:15889996; http://dx.doi.org/10.1586/ 14760584.4.2.229 25.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
J Immunol 2004; 172:6221-8; PMID:15128810; http://dx.doi.org/10.4049/jimmunol.172.10.622126.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Proteins 1997; 27:80-95; PMID:9037714; http://dx.doi.org/10.1002/(SICI)1097-0134(199701)27:1%3c80::AID-PROT9%3e3.0.,OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Proteins 1991; 10:270-8; PMID:1881883; http://dx.doi.org/10.1002/prot.340100311 29.,OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
ClinExp Immunol 2004; 136:365-72; PMID:15086403; http://dx.doi.org/10.1111/j.1365-2249.2004.02442.x 30.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Clin Exp Immunol 2001; 125:391-400; PMID:11531946; http://dx.doi.org/10.1046/j.1365-2249.2001.01525.x 31.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Vaccine 2010; 28:7035-46; PMID:20727394; http://dx.doi.org/10.1016/j.vaccine.2010.08.020 32.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
Immunol Lett 2014; 158:7-13; PMID:24269767; http://dx.doi.org/10.1016/j.imlet.2013.11.009 33.,Non-OADS,/arxiv_data1/oa_pdf/96/52/khvi-11-07-1038446.PMC4514271.pdf
"So door- to-door services may be helpful formigrant workers and should beKeywords: immunization, measles vac- cine, measles elimination, measles control,vaccine safety © Li Meina, Liu Xiaodong, and Zhang Lulu *Correspondence to: Zhang Lulu; Email:zllrmit@aliyun.com Submitted: 03/23/2015 Revised: 04/06/2015Accepted: 04/06/2015http://dx.doi.org/10.1080/21645515.2015.1039211 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/68/fb/khvi-11-07-1039211.PMC4514280.pdf
Available from: http://www.who.int/immunization/news-room/Measles_Rubella_S trategicPlan_2012_2020.pdf.,Non-OADS,/arxiv_data1/oa_pdf/68/fb/khvi-11-07-1039211.PMC4514280.pdf
Available from: http://www.chinadaily.com.cn/beijing/2015-01/28/con- tent_19435963.htm.,Non-OADS,/arxiv_data1/oa_pdf/68/fb/khvi-11-07-1039211.PMC4514280.pdf
Available from: http://www.bjcdc.org/article/39839/ 2015/3/1426149833114.html.,Non-OADS,/arxiv_data1/oa_pdf/68/fb/khvi-11-07-1039211.PMC4514280.pdf
Hum Vaccines Immunother 2015; 11:21-6; PMID:25483511; http://dx.doi.org/ 10.4161/hv.34298 6.,Non-OADS,/arxiv_data1/oa_pdf/68/fb/khvi-11-07-1039211.PMC4514280.pdf
Hum Vaccines Immunother 2014; 10:815; PMID:24784565; http://dx.doi.org/10.4161/ hv.29050 1778 Volume 11 Issue 7 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/68/fb/khvi-11-07-1039211.PMC4514280.pdf
"15Waning of vaccine-induced immunity has been suggested to play a role in these outbreaks.6-10,13,14When com- pared to the other components in the MMR vaccine, the mumps © Patricia Kaaijk, Sigrid Gouma, Hinke I Hulscher, Wanda G Han, Deborah E Kleijne, Rob S van Binnendijk, and C /C19ecile A van Els *Correspondence to: Patricia Kaaijk; Email: patricia.kaaijk@rivm.nlSubmitted: 02/06/2015; Revised: 03/26/2015; Accepted: 04/09/2015 http://dx.doi.org/10.1080/21645515.2015.1040967 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Proc Natl Acad Sci U S A 1994; 91:2464-8; PMID:8146140; http://dx.doi.org/ 10.1073/pnas.91.7.2464.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Vaccine 2004; 22:2713-6;PMID:15246601; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
N Engl J Med 2008; 358:1580-9; PMID:18403766; http://dx.doi.org/10.1056/NEJMoa0706589.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Clin Infect Dis 2007; 45:459-66; PMID:17638194; http://dx.doi.org/10.1086/520028.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Pediatr Infect Dis J 2010; 29:703-6; PMID:20308934; http://dx.doi.org/10.1097/INF.0b013e3181d743df.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
J Clin Virol 2012; 53:320-4; PMID:22269391; http://dx.doi.org/10.1016/j.jcv.2011.12.022.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Vaccine 2010; 28:2932-6; PMID:20188683; http://dx.doi.org/10.1016/j.vaccine.2010.02.020.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Vaccine 2014; 32:4393-8; PMID:24973734; http://dx.doi.org/10.1016/j.vaccine.2014.06.069.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Vaccine 2012; 30:4676-80; PMID:22579874; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
J Infect Dis 2012;206:1542-8; PMID:22966129; http://dx.doi.org/ 10.1093/infdis/jis568.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
J Infect Dis 2008; 198:508-15;PMID:18558869; http://dx.doi.org/10.1086/ 590115.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Epidemiol Infect 2000; 125:127-41;PMID:11057968; http://dx.doi.org/10.1017/ S0950268899004173.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
PLoS One2013; 8:e58234; PMID:23520497; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Open Forum Infect Dis 2014; 1(3): ofu101; PMID:25734169; http://dx.doi.org/ 10.1093/oﬁd/ofu101; Acce pted for publication.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Nature 1985; 318:323-9;PMID:3906406; http://dx.doi.org/10.1038/318323a0.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Am J Epidemiol 2006; 164:936-44; PMID:16968863; http://dx.doi.org/10.1093/aje/kwj317.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Emerg Infect Dis 2014; 20:643-8; PMID:24655811; http://dx.doi.org/10.3201/eid2004.131681.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
J Med Virol 1995; 45:17- 23; PMID:7714488; http://dx.doi.org/10.1002/ jmv.1890450104.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
J Med Virol 2008; 80:517- 23; PMID:18205215; http://dx.doi.org/10.1002/ jmv.21106.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
J Infect Dis2008; 197:1662-8; PMID:18419346; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
Clin Vaccine Immunol 2014; 21:286-97; PMID:24371258; http://dx.doi.org/ 10.1128/CVI.00621-13.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
J Virol Methods 2010; 163:153-6; PMID:19761798; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/23/khvi-11-07-1040967.PMC4514281.pdf
"A large percentage of © Sarah Lartey, Rishi D Pathirana, Fan Zhou, A/C14sne Jul-Larsen, Emanuele Montomoli, John Wood, and Rebecca Jane Cox *Correspondence to: Rebecca Jane Cox; Email: rebecca.cox@k2.uib.noSubmitted: 02/27/2015; Revised: 04/16/2015; Accepted: 05/04/2015 http://dx.doi.org/10.1080/21645515.2015.1048939 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
InﬂuenOther Res Viruses 2009; 3:207-13; PMID:19768134; http://dx.doi.org/10.1111/j.1750-2659.2009.00096.x 2.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
N Eng J Med 2009; 361:1945-52; PMID:19745214; http://dx.doi.org/ 10.1056/NEJMoa0906453 3.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
N Eng J Med 2009;360:2605-15; PMID:19423869; http://dx.doi.org/ 10.1056/NEJMoa0903810 4.,OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
73; PMID:21034828; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
FrontImmunol 2012; 3:87; PMID:22586427; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Nat Med2013; 19:1305-12; PMID:24056771; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Infect Dis 2012; 205:733-44; PMID:22315336; http://dx.doi.org/10.1093/infdis/jir641 13.,OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
"Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, Walravens K, Gillard P, Roman F.Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 inﬂuenza vaccine in healthy Japanese adults.Hum Vaccin Immunother 2012; 8:260-6; PMID:22426369; http://dx.doi.org/10.4161/hv.18469 14.",Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Hum Vaccin Immunother 2012; 8:1119-25; PMID:22854661; http://dx.doi.org/10.4161/hv.21081 15.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Infect Dis 2012; 206:1660-9; PMID:22969149; http://dx.doi.org/10.1093/infdis/jis589 16.,OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Vaccine2014; 32:1121-9; PMID:24252703; http://dx.doi.org/ 10.1016/j.vaccine.2013.11.031 17.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Infect Dis 2014; 210:1419-30; PMID:24864125; http://dx.doi.org/10.1093/infdis/jiu284 18.,OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Hum Vaccin Immunother 2012; 8:749-58; PMID:22495117; http://dx.doi.org/10.4161/hv.19684 19.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Hum Vaccin Immunother 2013; 9:1512-22; PMID:23571166; http://dx.doi.org/10.4161/hv.24504 20.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Vaccine 2013; 31:4389-97; PMID:23856331; http://dx.doi.org/ 10.1016/j.vaccine.2013.07.007 21.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Vaccine 1994; 12:167-74; PMID:8147099; http://dx.doi.org/ 10.1016/0264-410X(94)90056-6 23.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Vaccine 1994; 12:993-9; PMID:7975853; http://dx.doi.org/10.1016/0264- 410X(94)90334-4 24.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Immunol Rev 2011; 239:167-77; PMID:21198671; http://dx.doi.org/10.1111/j.1600- 065X.2010.00974.x 25.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Blood 2011; 118:2150-8; PMID:21690558; http://dx.doi.org/10.1182/blood-2011-04-345579 27.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Exp Med 2011; 208:2599-606; PMID:22162833;http://dx.doi.org/10.1084/jem.20110740 28.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Virol 2014; 88:13260-8; PMID:25210189; http://dx.doi.org/10.1128/JVI.02133-14 31.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Trend Immunol2014; 35:396-402; PMID:25043801; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Virol 2002; 76:1071-6; PMID:11773383; http://dx.doi.org/10.1128/JVI.76.3.1071-1076.2002 35.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Virol 2012; 86:6792-803;PMID:22491469; http://dx.doi.org/10.1128/ JVI.07172-11 36.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
PloS One 2013; 8:e57275; PMID:23526940; http://dx.doi.org/10.1371/ journal.pone.0057275 38.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Immunol 2011; 187:133-40;PMID:21642544; http://dx.doi.org/10.4049/ jimmunol.1002742 39.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Vaccine2009; 27:786-91; PMID:19027046; http://dx.doi.org/ 10.1016/j.vaccine.2008.11.003 40.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
J Immunol Methods 2004; 286:111-22; PMID:15087226; http://dx.doi.org/10.1016/j.jim.2003.12.015 43.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Pandemic inﬂuenza vaccination elicits inﬂuenza-speciﬁc CD4 CTh1-cell responses in hypogammaglobulinaemic patients: four case reports.Scand J Immunol 2011; 74:210-8; PMID:21438900; http://dx.doi.org/10.1111/j.1365-3083.2011.02561.x 44.,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
Cytometry Part A2011; 79:167-74; PMID:21265010; http://dx.doi.org/10.1002/cyto.a.21015 1662 Volume 11 Issue 7 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/65/ac/khvi-11-07-1048939.PMC4514283.pdf
"7-11The cancer diagnosis and treatment characteristics are not related to postcancer fatigue.6,12-16There is evidence, how- ever, that patients who receive only surgery have a decreased riskfor postcancer fatigue 11and patients who receive both surgery and adjuvant treatment have an increased risk for postcancer fatigue.7,17Cognitive behavior therapy (CBT), particularly © Hetty Prinsen, Hanneke WM van Laarhoven, Jeanette M Pots, Tjitske Duiveman-de Boer, Sasja F Mulder, Carla ML van Herpen, Joannes FM Jacobs, Jan Wille mH Leer, Gijs Bleijenberg, Foekje F Stelma, Ruurd Torensma, and I Jolanda M de Vries*Correspondence to: Hetty Prinsen; Email: hetty.prinsen@yale.eduSubmitted: 01/23/2015; Revised: 03/26/2015; Accepted: 04/08/2015 http://dx.doi.org/10.1080/21645515.2015.1040207 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Eur J Cancer 2002; 38:27-43; PMID:11750837; http://dx.doi.org/10.1016/S0959- 8049(01)00332-X.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Psychosom Res 2004; 56:157-70; PMID:15016573; http://dx.doi.org/10.1016/S0022-3999(03)00371-4.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Psychosom Res 1994; 38:383-92; PMID:7965927; http://dx.doi.org/ 10.1016/0022-3999(94)90099-X.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Cancer Nurs 1994; 17:367-78; PMID:7954384; http://dx.doi.org/ 10.1097/00002820-199410000-00001.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Br J Cancer 1993; 68:220-4; PMID:8347475; http://dx.doi.org/10.1038/ bjc.1993.319.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Cancer 2006; 106:751-8; PMID:16400678; http://dx.doi.org/10.1002/cncr.21671.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Clin Oncol 2005;23:6587-95; PMID:16170166; http://dx.doi.org/ 10.1200/JCO.2005.09.936.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Clin Oncol 2005; 23:8296-304; PMID:16219926;http://dx.doi.org/10.1200/JCO.2005.10.167.10.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Psychooncology 2007; 16:787-95; PMID:17086555; http://dx.doi.org/10.1002/pon.1120.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Onkologie 2003; 26:51-7; PMID:12624518; http://dx.doi.org/ 10.1159/000069864.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Ann Oncol 2004; 15:1237-42; PMID:15277264; http://dx.doi.org/ 10.1093/annonc/mdh314.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Bone Marrow Transplant 2007; 39:595-603; PMID:17369868; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Pain Symptom Manage 2000; 19:5-14; PMID:10687321; http://dx.doi.org/10.1016/S0885-3924(99)00138-4.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Support Care Cancer 2001; 9:11-7; PMID:11147137; http://dx.doi.org/ 10.1007/s005200000165.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Clin Oncol 2006; 24:4882-7; PMID:17050873; http://dx.doi.org/ 10.1200/JCO.2006.06.8270.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Oncologist 2007; 12 Suppl 1:22-34; PMID:17573453; http://dx.doi.org/10.1634/theoncologist.12-S1-22.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Brain Behav Immun 2007; 21:413-27; PMID:17178209; http://dx.doi.org/10.1016/j.bbi.2006.11.004.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Psychosom Med 2002; 64:604-11; PMID:12140350; http://dx.doi.org/10.1097/ 00006842-200207000-00010.22.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Brain Behav Immun 2003; 17 Suppl 1:S112-8; PMID:12615196; http://dx.doi.org/10.1016/S0889-1591(02)00077-6.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Psychoneuroendocrinology2005; 30:188-98; PMID:15471616; http://dx.doi.org/ 10.1016/j.psyneuen.2004.06.008.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Am J Psychiatry 2001; 158:1252-7; PMID:11481159; http://dx.doi.org/10.1176/appi.ajp.158.8.1252.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
BMC immunol 2012;13:71; PMID:23244635; http://dx.doi.org/10.1186/ 1471-2172-13-71.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Exp Med 2001; 193:1295-302; PMID:11390436; http://dx.doi.org/ 10.1084/jem.193.11.1295.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Pharmacol Ther 1998; 79:129-68; PMID:9749880; http://dx.doi.org/10.1016/S0163-7258(98)00013-8.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Mol Cell Biol 2011; 31:2066-78; PMID:21444725; http://dx.doi.org/ 10.1128/MCB.05155-11.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Clin Cancer Res2011; 17:4541-9; PMID:21712444; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Br J Cancer 2007; 97:612-8; PMID:17653075; http://dx.doi.org/10.1038/sj.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
Ann Oncol 2002; 13:589-98; PMID:12056710; http://dx.doi.org/10.1093/annonc/ mdf082.,OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
J Clin Oncol 2010; 28:2481-90; PMID:20385981; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c7/82/khvi-11-07-1040207.PMC4514289.pdf
"Split virus and subunit vaccines are the most widely used inﬂuenza vaccines; they retain the © Tracy Tay, Catherine Agius, Ross Hamilton, Jesse Bodle, and Steve Rockman *Correspondence to: Tracy Tay; Email: tracy.tay@biocsl.com.auSubmitted: 10/14/2014; Revised: 03/10/2015; Accepted: 03/24/2015 http://dx.doi.org/10.1080/21645515.2015.1034914 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
J Infect Dis 1977; 136:623-32; PMID:335000; http://dx.doi.org/10.1093/infdis/136.5.623 4.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Postgrad Med J 1973; 49:193-94; PMID:4802482; http://dx.doi.org/10.1136/pgmj.49.569.193 6.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Virology 1972; 50:640-52; PMID:4118317; http://dx.doi.org/ 10.1016/0042-6822(72)90418-7 7.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Annalen der Physik 1908; 330:377-445; http://dx.doi.org/10.1002/andp.19083300302 14.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Biochemistry 2000; 39:575-83; PMID:10642182; http://dx.doi.org/10.1021/bi991518m 15.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Proc Natl Acad Sci USA 1997; 94:7942-47; PMID:9223292; http://dx.doi.org/ 10.1073/pnas.94.15.7942 16.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Protein Sci 1998; 7:2642-52; PMID:9865959; http://dx.doi.org/10.1002/ pro.5560071218 17.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Int J Pharm 2008; 347:31-38; PMID:17692480; http://dx.doi.org/ 10.1016/j.ijpharm.2007.06.042 19.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Curr Pharm Biotechnol 2009; 10:359-72; PMID:19519411;http://dx.doi.org/10.2174/138920109788488815 20.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
J Chro- matogr 2004; 1033:241-45; http://dx.doi.org/ 10.1016/j.chroma.2004.01.040 21.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Curr Opin StructBiol 1996; 6:650-58; PMID:8913688; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Biochemistry 1972; 11:4013- 16; PMID:4673642; http://dx.doi.org/10.1021/ bi00772a001 26.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Protein Eng1992; 5:527-33; PMID:1438163; http://dx.doi.org/ 10.1093/protein/5.6.527 27.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Sci- ence 1993; 260:1456-65; PMID:8502990; http://dx.doi.org/10.1126/science.8502990 28.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Protein Sci 1993; 2:1520-31; PMID:8401236; http://dx.doi.org/10.1002/pro.5560020917 30.,OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
Biotechnol Genet Eng Rev 2007; 24:117- 28; PMID:18059629; http://dx.doi.org/10.1080/ 02648725.2007.10648095 31.,Non-OADS,/arxiv_data1/oa_pdf/3a/43/khvi-11-07-1034914.PMC4514297.pdf
"ﬁocruz.br; britto97@gmail.com Submitted: 07/09/2014; Revised: 09/25/2014; Accepted: 10/03/2014 http://dx.doi.org/10.4161/21645515.2014.990854 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Annu Rev Microbiol 1990; 44:649-88; PMID:2174669; http://dx.doi.org/10.1146/annurev.mi.44.100190.,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
AnnuRev Microbiol 2002; 56:371-402; PMID:12142476; http://dx.doi.org/10.1146/annurev.micro.56.012302.,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Hum Vaccin Immunother 2013:30-9; PMID:23364472; http://dx.doi.org/10.4161/hv.22982 7.,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
J Med Virol 1997; 53:212-7; PMID:9365884; http://dx.doi.org/10.1002/(SICI)1096-9071(199711)53:3%3c 212::AID-JMV5%3e3.0.CO;2-B 8.,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Pathol Res Pract 1992; 188:177-81; PMID:1594489; http://dx.doi.org/10.1016/S0344- 0338(11)81176-3 9.,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Nucleic Acids Res 2002; 30:1292-305; PMID:11884626; http://dx.doi.org/10.1093/nar/30.,OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
"ANVISA, 2003 http://www.anvisa.gov,br/legis/resol/ 2003/re/898_03re.htm (ANVISA – Ag ^encia Nacional de Vigil^ancia Sanit /C19aria, 2003.",Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Vaccine 2007;25:2941-50; PMID:16914238; http://dx.doi.org/ 10.1016/j.vaccine.2006.06.082 16.,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
J Virol Meth- ods 2003; 110:185-91; PMID:12798247; http://dx.doi.org/10.1016/S0166-0934(03)00129-0 17.,OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Virol J 2009; 23:6-10; PMID:19166574; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Rev Inst Med Trop S Paulo1995; 37:517-21; PMID:8731265; http://dx.doi.org/ 10.1590/S0036-46651995000600008 20.,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Clin Microbiol Newsletter 2007; 29; http://dx.doi.org/10.1016/j.clinmicnews.2007.05.002 21.,OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
Clin Microbiol Rev 2010; 23:550-76; PMID:20610823; http://dx.doi.org/ 10.1128/CMR.00074-09 www.tandfonline.com 1871 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/3d/7f/khvi-11-07-990854.PMC4514303.pdf
"16-18The WHO also recommends hepatitis A vac- cination over HNIG for both pre- and post-prophylaxis.16 © GlaxoSmithKline Biologicals SA *Correspondence to: Olivier Van Der Meeren; Email: olivier.x.van-der-meeren@gsk.comSubmitted: 12/23/2014; Revised: 04/10/2015; Accepted: 04/21/2015 http://dx.doi.org/10.1080/21645515.2015.1045167 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://www.who.int/csr/disease/hepatitis/HepatitisA_whocd scsredc2000_7.pdf?ua D1.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
World J Hepatol 2012; 4:68-73; PMID:22489258; http://dx.doi.org/10.4254/wjh.v4.i3.68 3.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Hum Vaccin Immunother 2012; 8:323-7;PMID:22327499; http://dx.doi.org/10.4161/hv.18617 4.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Epidemiol Rev 2006; 28:101-11;PMID:16775039; http://dx.doi.org/10.1093/epirev/ mxj012 5.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Infect Genet Evol 2014; 21:227-43; PMID:24200587; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
J Travel Med 2013; 20:394-9; PMID:24165384; http://dx.doi.org/10.1111/jtm.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 2014; 32:2939;PMID:24530928; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Expert Rev Vaccines 2005; 4:459- 71; PMID:16117704; http://dx.doi.org/10.1586/14760584.4.4.459 10.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
JAMA 1994; 271:1328-34; PMID:8158817; http://dx.doi.org/ 10.1001/jama.1994.03510410040030 11.,OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 2007; 25:927-31; PMID:17005304; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Lancet Infect Dis 2014; 14:976-81; PMID:25195178; http://dx.doi.org/10.1016/S1473-3099(14)70883-7 13.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://www.who.int/immuniza tion/position_papers/PP_hep_A_july2012_summary.,OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://www.eurosurveillance.org/images/dynamic/EQ/v06n01/v06n01.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://www.phac-aspc.gc.ca/publicat/ ccdr-rmtc/05vol31/dr3119b-eng.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://www.phac-aspc.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Availableat http://www.immunise.health.gov.au/internet/immu nise/publishing.nsf/Content/5-1.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://www.health.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 2014; 32:5509-13; PMID:25111168; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Arch Pediatr Adolesc Med 1996; 150:733-9; PMID:8673200; http://dx.doi.org/10.1001/archpedi.1996.02170320079014 25.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
J Med Virol 1994; 44:457-9; PMID:7897381; http://dx.doi.org/10.1002/jmv.1890440427 26.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin Infect Dis 1998; 27:531- 5; PMID:9770153; http://dx.doi.org/10.1086/514700 27.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 2001; 19:3615-9; PMID:11395194; http://dx.doi.org/10.1016/S0264-410X(01)00103-7 28.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Epidemiol Infect 1998; 121:377-80; PMID:9825788; http://dx.doi.org/10.1017/ S0950268898001411 30.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 2005; 23:2176-80; PMID:15755590; http://dx.doi.org/10.1016/j.vaccine.2005.01.044 31.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
World J Gastroenterol 2008; 14:2771-5; PMID:18461664; http://dx.doi.org/10.3748/wjg.14.2771 32.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://webarchive.nationalarchives.gov.uk/ 20140714084352/http://www.hpa.org.uk/webc/HPA webFile/HPAweb_C/1259152095231.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Available at http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
J Travel Med 1996; 3:156-9; PMID:9815444; http://dx.doi.org/10.1111/j.1708-8305.1996.tb00730.x 37.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Avail- able at http://www.cdc.gov/hepatitis/Outbreaks/2013/ A1b-03-31/index.html.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
J Med Virol 2001; 63:1-7;PMID:11130881; http://dx.doi.org/10.1002/1096- 9071(200101)63:1%3c1::AID-JMV1000%3e3.0.,OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
J Med Virol 1994; 44:443-5; PMID:7897378; http://dx.doi.org/ 10.1002/jmv.1890440424 42.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 2001; 19:4710-9;PMID:11535321; http://dx.doi.org/10.1016/S0264- 410X(01)00240-7 44.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Clin Infect Dis 2008; 47:401-9; PMID:18558875; http://dx.doi.org/10.1086/589862 46.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Am J Med 2005; 118(Suppl 10A):58S- 62S; PMID:16271543; http://dx.doi.org/10.1016/j.amjmed.2005.07.018 47.,OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 1993; 11:1027-32;PMID:8212822; http://dx.doi.org/10.1016/0264- 410X(93)90128-K 48.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Availbale at http://www.travelmedicine.it/ news/ectm3_abstract.pdf.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
PLoS One2012; 7:e31339; PMID:22355358; http://dx.doi.org/ 10.1371/journal.pone.0031339 52.,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
Vaccine 2003; 21:2234-7; PMID:12744848; http://dx.doi.org/10.1016/S0264-410X(03)00138-5 1734 Volume 11 Issue 7 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/f7/10/khvi-11-07-1045167.PMC4514304.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5a/2e/opth-9-1337.PMC4514311.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Ophthalmology 2015:9 1337–1345Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1337Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S7911 9Postcataract endophthalmitis prophylaxis  using irrigation, incision hydration, and eye  pressurization with vancomycin lee P schelonka1 Margaret a saBell2 1Department of Opthalmology, Kaiser  Permanente lone Tree Medical  Offices, lone Tree, 2Department  of infection Control, Kaiser  Permanente lone Tree Medical  Offices, lone Tree, Denver, CO, UsaPurpose:  This study aimed to determine whether switching from balanced salt solution (BSS)  to vancomycin 20 g/mL BSS for incision hydration and eye pressurization reduces the rate of  postcataract endophthalmitis.",Non-OADS,/arxiv_data1/oa_pdf/5a/2e/opth-9-1337.PMC4514311.pdf
"Internationally, the rate is as much  as ten times higher.5 Risk factors for endophthalmitis include age 85 years,2 posterior capsule rupture,6  clear corneal incisions (particularly when they leak on postoperative day 1),6,7 the  use of silicone (rather than acrylic or polymethyl methacrylate) intraocular lenses Correspondence: lee P schelonka Department of Opthalmology, Kaiser  Permanente Lone Tree Medical Offices,  10240 Park Meadows Drive, lone Tree,  Denver, CO 80124, Usa Tel +1 303 649 5431 Fax +1 303 649 5405 email leeschelonka@msn.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Schelonka and SaBell Running head recto: Postcataract endophthalmitis prophylaxis with vancomycin DOI: http://dx.doi.org/10.2147/OPTH.S79119",Non-OADS,/arxiv_data1/oa_pdf/5a/2e/opth-9-1337.PMC4514311.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/5a/2e/opth-9-1337.PMC4514311.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/2e/opth-9-1337.PMC4514311.pdf
Available  from: https://masshealthdruglist.ehs.state.ma.us/MHDL/pubtheradetail.,Non-OADS,/arxiv_data1/oa_pdf/5a/2e/opth-9-1337.PMC4514311.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ec/42/opth-9-1307.PMC4514312.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2015:9 1307–1314Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1307Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S8764 4long-term outcomes in patients undergoing  vitrectomy for retinal detachment due to viral  retinitis David rP almeida1 eric K Chin1 ryan M Tarantola1 elizabeth O T egins1 Christopher a lopez1 herbert Culver Boldt1 Karen M gehrs1 elliott h sohn1 stephen r russell1 James C Folk1 Vinit B Mahajan1,2 1Department of Ophthalmology and  Visual sciences, 2Omics laboratory,   University of iowa hospitals and  Clinics, iowa City, ia, UsaPurpose:  To determine the outcomes in patients with rhegmatogenous retinal detachment  (RRD) secondary to viral retinitis.",Non-OADS,/arxiv_data1/oa_pdf/ec/42/opth-9-1307.PMC4514312.pdf
"CMV is much more common in immunocompromised patients.8–10 Polymerase  chain-reaction (PCR) analysis of aqueous and vitreous samples is the gold standard  for diagnosis (sensitivity 95%, specificity 97%),11–13 and for monitoring disease course Correspondence: Vinit B Mahajan University of iowa Carver College  of Medicine, 200 hawkins Drive,  iowa City, ia 52242, Usa Tel +1 319 356 3185 Fax +1 319 356 0363 email vinit-mahajan@uiowa.ed u Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Almeida et al Running head recto: Outcomes in RRD secondary to viral retinitis  DOI: http://dx.doi.org/10.2147/OPTH.S87644",Non-OADS,/arxiv_data1/oa_pdf/ec/42/opth-9-1307.PMC4514312.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/ec/42/opth-9-1307.PMC4514312.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ec/42/opth-9-1307.PMC4514312.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/df/dc/ijn-10-4593.PMC4514313.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 4593–4603International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4593OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8378 8Increased osteoblast function in vitro and in vivo  through surface nanostructuring by ultrasonic  shot peening Y ongyuan guo1,* Beibei hu2,* chu Tang1 Yunpeng Wu1 Pengfei sun1 Xianlong Zhang3 Yuhua Jia1 1Orthopaedic Department, 2Medical  examination center, Qilu hospital  of shandong University, Jinan,   3Orthopaedic Department, The  sixth affiliated People’s hospital,   Medical school of  shanghai Jiao Tong  University, shanghai, People’s republic  of china *These authors contributed equally  to this workAbstract:  Surface topography has significant influence on good and fast osseointegration of  biomedical implants.",Non-OADS,/arxiv_data1/oa_pdf/df/dc/ijn-10-4593.PMC4514313.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/df/dc/ijn-10-4593.PMC4514313.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/df/dc/ijn-10-4593.PMC4514313.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/86/32/ppa-9-1023.PMC4514314.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2015:9 1023–1031Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1023OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S8557 7Association of neutrophil/lymphocyte ratio with  obstructive coronary artery disease and coronary  artery calcium score detected by multislice computed  tomography in type 2 diabetes mellitus patients Fatih Aygün1 Duran efe2 1Department of cardiovascular  surgery, Konya Medical and  Research Center, Başkent University,   2Department of radiology, Faculty  of Medicine, Mevlana University,   Konya, T urkeyObjective:  The aim of the present study was to investigate the association of neutrophil/ lymphocyte ratio (NLR) with coronary artery calcium score (CACS) and obstructive coronary  artery disease (CAD) detected by multislice computed tomography (MSCT) angiography in  type 2 diabetes mellitus (T2DM) patients.",Non-OADS,/arxiv_data1/oa_pdf/86/32/ppa-9-1023.PMC4514314.pdf
"If T2DM can be early diagnosed, T2DM-related  diseases such as cardiovascular disease and systemic complications can be prevented.5  Atherosclerosis is a T2DM-related problem, and it is a source of cardiovascular disease.6 correspondence: Fatih Aygün hocacihan Mahalle saray cad no 1,  42000 Selçuklu, Konya, Turkey Tel +90 332 322 94 10 Fax +90 332 322 94 19 email fatihaygun@ttmail.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Aygün and Efe Running head recto: Relationship of NLR with CAD and CCS in type 2 T2DM patients DOI: http://dx.doi.org/10.2147/PPA.S85577",Non-OADS,/arxiv_data1/oa_pdf/86/32/ppa-9-1023.PMC4514314.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/86/32/ppa-9-1023.PMC4514314.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bf/b1/ndt-11-1781.PMC4514315.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 1781–1784Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1781Case repor Topen access to scientific and medical research open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8773 1acute multiple focal neuropathies and delayed  postanoxic encephalopathy after alcohol  intoxication Wei-Che Wang Hsiu-Chun Yang Yao-Jen Chen Department of p hysical Medicine and  rehabilitation, Chung shan Medical  University Hospital, Taichung, TaiwanAbstract:  Acute-onset alcohol-associated neuropathy is only occasionally reported, and delayed  postanoxic encephalopathy is rare.",Non-OADS,/arxiv_data1/oa_pdf/bf/b1/ndt-11-1781.PMC4514315.pdf
"The patient drank two bottles Correspondence: Yao-Jen Chen Department of physical Medicine and  rehabilitation, Chung shan Medical  University Hospital, 110 section 1 Chien- Kuo North road, Taichung 402, Taiwan Tel +886 4 2473 9595 ext 21 700 Fax +886 4 2471 0934 email yj.chen1960@gmail.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Case report Y ear: 2015 Volume: 11 Running head verso: Wang et al Running head recto: Alcohol-related neuropathy DOI: http://dx.doi.org/10.2147/NDT.S87731",Non-OADS,/arxiv_data1/oa_pdf/bf/b1/ndt-11-1781.PMC4514315.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/bf/b1/ndt-11-1781.PMC4514315.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/bf/b1/ndt-11-1781.PMC4514315.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/db/0d/clep-7-335.PMC4514316.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Epidemiology 2015:7 335–345Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  335Original rEsEarChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CLEP .S8549 6Prevalence of bone metastases and bone-targeting  agent use among solid tumor patients in the  United states rohini K hernandez1  avanti adhia2  sally W Wade3  Emily O’Connor1  Jorge arellano1  Kevin Francis2  hasmik alvrtsyan4  ryan P Million4  alexander liede5 1amgen inc., Thousand Oaks, C a,   2Trinity Partners, Waltham, M a, 3Wade  Outcomes research and Consulting,   salt lake City, UT, 4Trinity Partners,   new Y ork, nY, 5amgen inc., south san  Francisco, C a, Usa Correspondence: alexander liede   Cancer Epidemiology, Center for  Observational research, amgen inc.,   1120 Veterans Blvd, asF3, south san  Francisco, Ca  94080, Usa   Tel +1 65 0244 2418  Fax +1 80 5447 1984  Email aliede@amgen.co mPurpose:  Patients with bone metastases are at an increased risk of experiencing morbidity  due to bone complications, and bone-targeting agents (BTA) are indicated for the prevention of  these complications.",Non-OADS,/arxiv_data1/oa_pdf/db/0d/clep-7-335.PMC4514316.pdf
Available from: http://www.xgeva.,Non-OADS,/arxiv_data1/oa_pdf/db/0d/clep-7-335.PMC4514316.pdf
"Available from: http://seer.cancer.gov/statfacts/ html/breast.htm l. Accessed September  12, 2014.",Non-OADS,/arxiv_data1/oa_pdf/db/0d/clep-7-335.PMC4514316.pdf
Available from: http://seer.cancer.gov/statfacts/html/prost.,OADS,/arxiv_data1/oa_pdf/db/0d/clep-7-335.PMC4514316.pdf
"Available from: http://seer.cancer.gov/statfacts/ html/lungb.htm l. Accessed September  12, 2014.",Non-OADS,/arxiv_data1/oa_pdf/db/0d/clep-7-335.PMC4514316.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-epidemiology-journa lClinical Epidemiology is an international, peer-reviewed, open access,  online journal focusing on disease and drug epidemiology, identifica - tion of risk factors and screening procedures to develop optimal pre - ventative initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/db/0d/clep-7-335.PMC4514316.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4f/b1/ott-8-1753.PMC4514317.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 1753–1760OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1753Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S8613 6IL-2 -330T/g polymorphism and cancer risk:  a meta-analysis hongyu Zhao1,* rui Wang2,* 1central laboratory, The second  affiliated hospital of southeast  University, nanjing, 2nanjing Kingmed  clinical laboratory co., ltd, nanjing,   Jiangsu, People’s republic of china *These authors contributed equally  to this work and share the first  authorshipPurpose:  Some studies have investigated the association of IL-2 -330T/G (rs2069762)  polymorphism with cancer risk, but the previous results were conflicting and had relatively  low statistical power.",Non-OADS,/arxiv_data1/oa_pdf/4f/b1/ott-8-1753.PMC4514317.pdf
"In IgM-expressing  B cells, IL-2 and IL-5 act synergistically to upregulate expression of heavy and correspondence: hongyu Zhao Central Laboratory, The Second Affiliated  hospital of southeast University,  1-1 Zhongfu street, 210003 nanjing,  People’s republic of china email zhaohy1223@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Zhao and Wang Running head recto: IL- 2 -330T/G polymorphism and cancer risk DOI: http://dx.doi.org/10.2147/OTT.S86136",Non-OADS,/arxiv_data1/oa_pdf/4f/b1/ott-8-1753.PMC4514317.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/4f/b1/ott-8-1753.PMC4514317.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/4f/b1/ott-8-1753.PMC4514317.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/51/04/ndt-11-1767.PMC4514318.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 1767–1779Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1767OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8773 7individual correlates of self-stigma in patients with  anxiety disorders with and without comorbidities Marie Ociskova1,2 Jan Prasko1 Dana Kamaradova1 ales grambal1 Zuzana sigmundova1 1Department of Psychiatry, University  hospital in Olomouc, Faculty of  Medicine and Dentistry, 2Department  of Psychology, Faculty of arts, Palacky  University in Olomouc, Olomouc,   czech republicBackground:  A number of psychiatric patients experience stigma connected to prejudices about  mental disorders.",Non-OADS,/arxiv_data1/oa_pdf/51/04/ndt-11-1767.PMC4514318.pdf
"They are deeply rooted culturally and are perpetuated by folklore and mass  media.1 Prejudices concerning mental health issues and persons who suffer from them  are often related to the expected dangers associated with psychiatric patients.1 The fears  that stem from these prejudices do not take into consideration that most individuals  with mental disorders are not violent or aggressive.2 Still, prejudices and the emotions correspondence: Marie Ociskova Department of Psychiatry, University  hospital Olomouc, i P Pavlova 6, 775 20  Olomouc, czech republic Tel +420 58 844 3513 email marie.ociskova@upol.c z Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Ociskova et al Running head recto: Self-stigma in patients with anxiety disorders DOI: http://dx.doi.org/10.2147/NDT.S87737",Non-OADS,/arxiv_data1/oa_pdf/51/04/ndt-11-1767.PMC4514318.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/51/04/ndt-11-1767.PMC4514318.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/51/04/ndt-11-1767.PMC4514318.pdf
"2 From our own research and that of others, some key barriers to HPV vaccina-tion at ages 11-12 include: (1) parents’concerns that preteen children are too young to get vaccinated and are not sexu- ally active yet, that the vaccine is not safe,and they do not have a vaccine recommen-dation from their doctor; (2) preteens’ dis-like of shots and being minimally involvedin the vaccination decision, and (3)Keywords: HPV, HPV vaccination, pre- teen, social marketing, sexually transmit-ted infection, STI © Joan R Cates and Tamera Coyne-Beasley *Correspondence to: Joan R Cates; Email: JoanCates@unc.edu Submitted: 10/02/2014 Accepted: 10/11/2014 http://dx.doi.org/10.4161/21645515.2014.994458 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
A Report to the President of the United States from the Presi- dent’s Cancer Panel 2014. http://deainfo.nci.nih.gov/ advisory/pcp/annualReports/HPV/index.htm 4.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
Hum Vaccin Immunothera 09/01 2014; 10(9):0-1; http://dx.doi.org/10.4161/hv.28596 6.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
Hum Vac- cin Immunother 09/01 2014; 10(9):0-1; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
J Adolesc Health 2010; 46 (2):113-123; PMID:20113917; http://dx.doi.org/10.1016/j.jadohealth.2009.11.199 9.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
J Adolesc Health 2010; 47(1):3-11; PMID:20547286; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
Sex Transm Dis 2011; 38(3):197-204; PMID:20838362; http://dx.doi.org/10.1097/OLQ.0b013e3181f12dbf 11.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
MMWR 2013; 61(34);671-677(33):1117-1123. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm 6134a3.htm?s_cid=mm6134a3_w.,OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
PMID:22405151; http://dx.doi.org/10.1363/ 4403912 15.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
PMID:24886960; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
2013; http://www.publichealthmdc.com/ DCIC/documents/D CICmin20130514HPVComm Part1.pdf.,OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
Vaccine 3/20/ 2014; 32(14):1527-1535; PMID:24581979;http://dx.doi.org/10.1016/j.vaccine.2013.07.087 24.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
Am J Public Health 2013; 103 (9):1693-1699; PMID:23865659; http://dx.doi.org/ 10.2105/AJPH.2012.301165 25.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
Fam Pract 2008 ; 25(suppl 1):i20-i24; PMID:18794201; http://dx.doi.org/10.1093/fampra/ cmn055 27.,Non-OADS,/arxiv_data1/oa_pdf/c5/46/khvi-11-02-994458.PMC4514322.pdf
"14,15The results of these tri als are promising, but© Jens Bedke, Stephan Kruck, Georgios Gakis, Arnulf Stenzl, and Peter J Goebell *Correspondence to: Jens Bedke; Email: bedke@live.com Submitted: 10/21/2014; Revised: 01/06/2015; Accepted: 01/19/2015http://dx.doi.org/10.1080/21645515.2015.1016657 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Eur Urol 2010; 58(3):398–406;PMID:20633979; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
J Urol 2004; 171(3):1071–6; PMID:14767273; http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
J Clin Oncol 2009; 27(22):3584–90; PMID:19487381; http://dx.doi.org/10.1200/JCO.2008.20.1293 5.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
N Engl J Med 2014; 370 (18):1769–70; PMID:24785224; http://dx.doi.org/10.1056/NEJMc1400731 6.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Lancet 2011; 378(9807):1931–9; PMID:22056247; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
"Exp Rev Antican Ther 2012; 12(6):777–85; PMID:22716494; http://dx.doi.org/ 10.1586/era.12.43 8. van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA.",OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Clin Cancer Res 2007; 13(7):2100–08;PMID:17404092; http://dx.doi.org/10.1158/1078- 0432.CCR-06-1662 9.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Blood 2006; 107(6):2409–14;PMID:16304057; http://dx.doi.org/10.1182/blood- 2005-06-2399 10.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
"Exp Rev Antican Ther 2013; 13(12):1399–408;PMID:24215158; http://dx.doi.org/10.1586/ 14737140.2013.856761 11. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.",Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Sciencel 1991;254(5038):1643–7; PMID:1840703; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Lancet 2008; 372 (9633):145–54; PMID:18602688; http://dx.doi.org/10.1016/S0140-6736(08)60697-2 14.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Lancet 2004; 363(9409):594–9;PMID:14987883; http://dx.doi.org/10.1016/S0140- 6736(04)15590-6 15.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
"Nat Med 2012; 18(8), 1254–61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883 16.",OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
http://clinicaltrials.gov/ct2/show/NCT01265901).,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
http://clinicaltrials.gov/show/NCT01582672).,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Nat Immun 2002; 3(11):991–8; PMID:12407406; http://dx.doi.org/10.1038/ni1102- 991 20.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
CurrOpin Immunol 2010; 22(2):231–7; PMID:20144856; http://dx.doi.org/10.1016/j.coi.2010.01.009 22.,OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
World J Urol 2014; 32(1); 31–8;PMID:23404195; http://dx.doi.org/10.1007/s00345- 013-1033-3 23.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
J Clin Invest 2007; 117(5):1167–74; PMID:17476346; http://dx.doi.org/10.1172/JCI31202 24.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Clin Cancer Res 2008; 14(24):8270–8; PMID:19088044; http://dx.doi.org/10.1158/1078-0432.CCR-08-0165 25.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Ann Rev Immunol 2005; 23:515–48; PMID:15771580; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Ann Rev Immunol 2001; 19:225–52;PMID:11244036; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Nat Immunol 2005; 6(3):280–6; PMID:15685176; http://dx.doi.org/10.1038/ni1165 28.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Ann Rev Immunol 2003; 21:685– 711; PMID:12615891; http://dx.doi.org/10.1146/ annurev.immunol.21.120601.141040 29.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
J Exp Med 1991; 173(3):721–30; PMID:1847722; http://dx.doi.org/10.1084/jem.173.3.721 30.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
"J Exp Med 1991; 174(3), 561–9; PMID:1714933; http://dx.doi.org/10.1084/ jem.174.3.561 31.",Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Trends Immunol 2003; 24(6):314–9; PMID:12810107; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
PMID:7584144; http://dx.doi.org/10.1016/1074- 7613(95)90125-6 34.,OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
N Engl J Med 2010; 363(8):711–23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 36.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
N Engl J Med 2011; 364(26):2517–26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621 37.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
J Clin Oncol2013; 31(5):616–22; PMID:23295794; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
J Immunothera 2007; 30(8):825–30; PMID:18049334; http://dx.doi.org/10.1097/CJI.0b013e318156e47e 39.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Cancer 2011; 117(4):758–67; PMID:20922784; http://dx.doi.org/10.1002/ cncr.25639 40.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Nat Med 2003; 9(5):562–7; PMID:12704383; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
N Engl J Med 2012; 366(26):2455– 65; PMID:22658128; http://dx.doi.org/10.1056/ NEJMoa1200694 44.,OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
N Engl J Med 2012;366(26):2443–54; PMID:22658127; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Oncoimmunology 2014; 3(1):e27297; PMID:24701370; http://dx.doi.org/10.4161/ onci.27297 46.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Lancet 2014; 384(9948):1109–17; PMID:25034862; http://dx.doi.org/ 10.1016/S0140-6736(14)60958-2 54.,OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
J Clin Oncol 2013; 31(33):4199– 4206; PMID:24127452; http://dx.doi.org/10.1200/JCO.2012.48.3685 56.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Nature 2014; 515(7528):558–62; PMID:25428503; http://dx.doi.org/10.1038/nature13904 58.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
Clin Can-cer Res 2009; 15(19):6225–6231; PMID:19755389; http://dx.doi.org/10.1158/1078-0432.CCR-09-0068 1208 Volume 11 Issue 5 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/77/d1/khvi-11-05-1016657.PMC4514323.pdf
"Direct axonal injury may be implicated in the casereported by Ling and Loong 11in which a 47 year old male© Ian F Cook *Correspondence to: Ian F Cook; Email: drifcook@bigpond.com Submitted: 11/25/2014; Revised: 01/25/2015; Accepted: 02/06/2015http://dx.doi.org/10.1080/21645515.2015.1017694 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Biologicals 2012; 40:384-8; PMID:21993306; http://dx.doi.org/ 10.1016/j.biologicals.2011.08.001 2.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2013; 31:1431-7; PMID:22766247; http://dx.doi.org/10.1016/j.vaccine.2012.06.030 4.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2011; 29:3000-8; PMID:21569813; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Phys Med Rehabil Clin N Am 2013; 24:33-47; PMID:23177029; http://dx.doi.org/10.1016/j.pmr.2012.08.018 6.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Clin Neu-rophysiol 2010; 121(Supp 1):S231; http://dx.doi.org/ 10.1016/S1388-2457(10)60944-3 9.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
JAMA 1966; 198:166-7; PMID:4288653; http://dx.doi.org/10.1001/jama.1966.03110220114041 10.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Am J Phys Med Rehabil 2007;86:501-1; PMID:17515691; http://dx.doi.org/ 10.1097/PHM.0b013e31805b7bcf 13.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
J Shoulder Eblow Surg 2001; 5:493-5; http://dx.doi.org/10.1067/mse.2001.114682 16.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Eur Radiol 2000; 10:242-9; PMID:10663753; http://dx.doi.org/ 10.1007/s00330005004017.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Skeletal Radiol 2014; 43:1325-31; PMID:24722656; http://dx.doi.org/10.1007/s00256-014-1875-9 19.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
J Am Board Fam Med 2012; 25:919-22; PMID:23136333; http://dx.doi.org/10.3122/jabfm.2012.06.110334 20.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2011; 29:6830-3; PMID:21803092; http://dx.doi.org/ 10.1016/j.vaccine.2011.07.052 22.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Orthopedics 2012; 35: e.283-6; PMID:22310421; http://dx.doi.org/ 10.3928/01477447-20120123-26 23.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
JAMA 2009; 19:750-7; PMID:19690307; http://dx.doi.org/10.1001/jama.2009.1201 24.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2007; 25:585-7; PMID: 17064824; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Hum Vaccin Immunother2014; 3:605-6; PMID:24284281; http://dx.doi.org/ 10.4161/hv.27232 28.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vac- cine 2010; 28:8049-52; PMID:20955829; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
J Shoulder Elbow Surg 2011; 20:322-5; PMID:21051244; http://dx.doi.org/ 10.1016/j.jse.2010.07.008 32.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2004; 22:575-85; PMID:14741147; http://dx.doi.org/ 10.1016/j.vaccine.2003.09.005 34.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2002; 20:1412-20; PMID:11818160; http://dx.doi.org/10.1016/S0264- 410X(01)00462-5 35.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2014; 32:1019-28; PMID:24373307; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2003; 21:4335-47; PMID:14505916; http://dx.doi.org/10.1016/S0264-410X(03)00460-2 38.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
J Am Acad Dermatol 2001;45:325-61; PMID:11511831; http://dx.doi.org/ 10.1067/mjd.2001.114735 39.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2009; 27:4876-8;PMID:19555713; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2011; 29:2576-81; PMID:21296693; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2011; 29:1123-5; PMID:21172376; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Int J Dermatol 2007; 46:1050-64; PMID:17910713; http://dx.doi.org/10.1111/ j.1365-4632.2007.03268.x 44.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Lancet 1996; 347(9013):1484; PMID:8676651; http://dx.doi.org/10.1016/S0140-6736(96)91719-5 45.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
PMID:16871038; http://dx.doi.org/10.1097/ 00000372-200608000-00008 46.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2007; 25:4767-74; PMID:17512098; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2007; 25:5821-38; PMID:17540485; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Am J Pub Health1954; 44:1314-1325; PMID:13197608; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Rev Soc Bras Med Trop 1996; 29:497- 501; PMID:8885674; http://dx.doi.org/10.1590/ S0037-86821996000500014 52.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
J Hand Surg 2005; 308:482-3; PMID:15993993; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Am J Pub Health 1950; 40:681-5;PMID:15413709; http://dx.doi.org/10.2105/ AJPH.40.6.681 54.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2007; 25:5803-20; PMID:17548135; http://dx.doi.org/10.1016/j.vaccine.2007.04.059 55.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
South Med J 1997; 90:752-4; PMID:9225903; http://dx.doi.org/10.1097/00007611-199707000-00022 57.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
AllergyAsthma Proc 2008; 29:397-9; PMID:18702888; http://dx.doi.org/10.2500/aap.2008.29.3144 58.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Pediatr InfectDis J 2008; 27:937-9; PMID:18776824; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Hum Vaccin Immunother 2014; 10:1-4; PMID:24832715; http://dx.doi.org/10.4161/hv.28050 60.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Pediatrics 2011; 127:S45-S53; PMID:21502240; http://dx.doi.org/10.1542/peds.2010-1722H 61.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccin e 2014; 32(48):6360-3; PMID:25252195; http://dx.doi.org/10.1016/j.vaccine.2014.09.017 69.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
J Shoulder Elbow Surg 2009; 18:748-55; PMID:19278875; http://dx.doi.org/ 10.1016/j.jse.2008.12.001 83.,OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
JAMA 1997; 277:1709- 11; PMID:9169899; http://dx.doi.org/10.1001/jama.1997.03540450065037 84.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2006; 24:937-40; PMID:16191454; http://dx.doi.org/ 10.1016/j.vaccine.2005.08.098 85.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Vaccine 2013; 31:2647-52; PMID:23566948; http://dx.doi.org/ 10.1016/j.vaccine.2013.03.037 86.,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
Arch Dis Child 2007;92:1105-8; PMID:17686797; http://dx.doi.org/ 10.1136/adc.2007.118695 www.tandfonline.com 1191 Human Vaccines & Immunotherapeutics,Non-OADS,/arxiv_data1/oa_pdf/6b/95/khvi-11-05-1017694.PMC4514326.pdf
"7A tetravalent conjugate vaccine has been developed at Sanoﬁ-Pasteur8that incorporates polysaccharides from groups A, © Abel E Vasquez, Ricardo A Manzo, Daniel A Soto, Magaly J Barrientos, Aurora E Maldonado, Macarena Mosqueira, Anastasia Avila, Jorge Touma, Elsa Bruc e, Paul R Harris, and Alejandro Venegas*Correspondence to: Alejandro Venegas; Email: alejandro.venegas@udp.clSubmitted: 07/31/2014; Revised: 10/27/2014; Accepted: 11/11/2014 http://dx.doi.org/10.1080/21645515.2015.1011011 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807 2.,OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2012; 30 Suppl 2: B26-36; PMID:22178525; http://dx.doi.org/10.1016/j.vaccine.2011.12.032 5.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
2005;5:21-30; PMID:15620558; http://dx.doi.org/10.1016/ S1473-3099(04)01251-4 6.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2006; 24:4692-700; PMID:16621189;http://dx.doi.org/10.1016/j.vaccine.2006.03.034 7.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
J Infect Dis 2001; 183:160-3; PMID:11078484; http://dx.doi.org/10.1086/317646 8.,OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
2009; 27 Suppl 2:B30-41; PMID:19477560; http://dx.doi.org/ 10.1016/j.vaccine.2009.05.003 10.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Lancet 2012; 379: 617-24;PMID:22260988; http://dx.doi.org/10.1016/S0140- 6736(11)61713-3 14.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Lan- cet 2002; 359:1499-508; PMID:11988262; http://dx.doi.org/10.1016/S0140-6736(02)08416-7 19.,OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 1995; 13:821-9; PMID:7483804; http://dx.doi.org/10.1016/0264- 410X(94)00037-N 20.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Lancet 1992; 340:1074-8; PMID:1357461; http://dx.doi.org/10.1016/0140-6736(92)93086-3 21.,OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
"Available from: http://pubmlst.org/neis seria/PorA/ 28 Luijkx TA, van Dijken H, Hamstra H-J, Kuipers B, van der Ley P, van Alphen L, van den Dobbelsteen G. Rela- tive immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent onpresentation form.",Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Infect Immun 2003; 71: 6367-71; PMID:14573657; http://dx.doi.org/10.1128/IAI.71.11.6367-6371.2003 29.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2007; 25: 2491-6;PMID:17023098; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2013; 31:1065-71; PMID:23273968; http://dx.doi.org/10.1016/j.vaccine.2012.12.031 32.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 1999; 17:2612-9; PMID:10418910; http://dx.doi.org/ 10.1016/S0264-410X(99)00044-4 33.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2002; 20:2592-6; PMID:12057617; http://dx.doi.org/10.1016/S0264-410X(02)00151-2 34.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2003; 21: 950- 60; PMID:12547608; http://dx.doi.org/10.1016/S0264-410X(02)00546-7 35.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Nature 1984; 308:457-60; PMID:6709052;http://dx.doi.org/10.1038/308457a0 37.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Adv Drug Del Rev 1998; 34:321-38; PMID:10837684ND; http://dx.doi.org/10.1016/S0169-409X(98)00046-5 38.,OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2004; 22:5164-9; PMID:15063582; http://dx.doi.org/10.1016/j.vaccine.2003.09.042 40.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
2000; 68(9):4938- 47; PMID:10948108; http://dx.doi.org/10.1128/ IAI.68.9.4938-4947.2000 48.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
2014 5; 32(27):3393-401; PMID:24768634; http://dx.doi.org/10.1016/j.vaccine.2014.04.018 49.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2008; 26:786-96; PMID:18191311; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
J Med Micro-biol 2008; 57:338-42PMID:18287297; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
"Vaccine 2009; 27 (Supp 2):B3-B12; PMID:19481313; http://dx.doi.org/ 10.1016/j.vaccine.2009.04.071 60. de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, R €umke H, de Groot R, van Alphen L, van den Dobbelsteen G. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.",Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 2001; 20:352-8;PMID:11672897; http://dx.doi.org/10.1016/S0264- 410X(01)00371-1 61.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Mol Microbiol 2005; 58:1216-25; PMID:16313611; http://dx.doi.org/10.1111/j.1365-2958.2005.04906.x 62.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Vaccine 1999; 17:754-64; http://dx.doi.org/ 10.1016/S0264-410X(98)00259-X66.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
Future Microbiol 2010; 5:749-58; PMID:20441547; http://dx.doi.org/10.2217/fmb.10.41 75.,Non-OADS,/arxiv_data1/oa_pdf/51/1a/khvi-11-03-1011011.PMC4514328.pdf
"20-26 Indeed, it is not known at what age the magnitude of the immune response to hepatitis B vaccination starts to reduce, or until what age the immune response remains acceptable (for © GlaxoSmithKline Biologicals SA *Correspondence to: Olivier Van Der Meeren; Email: olivier.x.van-der-meeren@gsk.comSubmitted: 02/17/2015; Revised: 03/26/2015; Accepted: 04/07/2015 http://dx.doi.org/10.1080/21645515.2015.1039758 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Lancet Infect Dis 2002; 2:659-66; PMID:12409046; http://dx.doi.org/10.1016/S1473-3099(02)00437-1 3.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
KidneyBlood Press Res 2012; 35:454-67; http://dx.doi.org/ 10.1159/000338309 4.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Am J Med 2005; 118 (Suppl 10A):21S-27S;PMID:16271537; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
J Clin Gastroenterol 2000; 30:250-4; PMID:10777182; http://dx.doi.org/10.1097/00004836-200004000- 00009 6.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Gastroenterology 2004;126:460-8; PMID:14762783; http://dx.doi.org/ 10.1053/j.gastro.2003.10.065 7.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Clin Infect Dis 2013; 57:1695-702; PMID:24051864; http://dx.doi.org/10.1093/cid/cit603 8 .,OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
J Diabetes Sci Technol 2012; 6:858-66; PMID:22920812; http://dx.doi.org/10.1177/ 193229681200600417 9.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Age (Dordr) 2014; 36:313-51; PMID:23877171; http://dx.doi.org/10.1007/s11357- 013-9564-5 11.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Goldstein DR. Role of aging on innate responses to v i r a li n f e c t i o n s .JG e r o n t o lAB i o lS c iM e dS c i 2012; 67:242-6; PMID:22042722; http://dx.doi.org/10.1093/gerona/glr194 12.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Semin Immunol 2012; 24:342-9; PMID:22560930; http://dx.doi.org/ 10.1016/j.smim.2012.04.004 13.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Hum VaccinImmunother 2013; 9:1364-7; PMID:23584248; http://dx.doi.org/ 10.4161/hv.24696 14.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Curr Med Res Opin 2007;23:2729-39; PMID:17897485; http://dx.doi.org/ 10.1185/03007X233034 16.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Eur J Emerg Med 2006;13:67-71; PMID:16525231; http://dx.doi.org/ 10.1097/01.mej.0000184993.51799.ad 17.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 2011; 29:5932-9; PMID:21718738; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Clin Infect Dis 2008; 46:1078-84; PMID:18444828; http://dx.doi.org/10.1086/529197 20.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 1994; 12:532-4; PMID:8036828; http://dx.doi.org/10.1016/0264-410X(94)90313-1 21.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 2012;30:3147-50; PMID:22421557; http://dx.doi.org/ 10.1016/j.vaccine.2012.02.078 22.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
J Infect Dis 1984; 149:1019;PMID:6234369; http://dx.doi.org/10.1093/infdis/ 149.6.1019 23.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 2003; 21: 3623-8; PMID:12922091; http://dx.doi.org/ 10.1016/S0264-410X(03)00399-2 2 4 .,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Expert Rev Vaccines 2003; 2:9-14;PMID:12901592; http://dx.doi.org/10.1586/ 14760584.2.1.9 25.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 2006; 24:5509-15; PMID:16725234; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
J Clin Virol 2013;58:262-4; PMID:23895931; http://dx.doi.org/ 10.1016/j.jcv.2013.07.003 27.,OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Clin Vaccine Immunol 2010; 17:1055- 65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10 28.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
J InfectDis 1999; 179:489-92; PMID:9878036; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
J Pathol 2007; 211:144-56; PMID:17200946; http://dx.doi.org/10.1002/ path.2104 30.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 2010; 28:589-90; PMID:19896455; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 2000; 19:437-41; PMID:11027806;http://dx.doi.org/10.1016/S0264-410X(00)00205-X 34.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
Vaccine 2001; 19:4710-9; PMID:11535321; http://dx.doi.org/10.1016/S0264- 410X(01)00240-7 35.,Non-OADS,/arxiv_data1/oa_pdf/65/ef/khvi-11-07-1039758.PMC4514334.pdf
"However, although subjects who permanently carry S. aureus are at increased risk of staphylo- coccal bacteremia, they have a lower infection-related mortality rate 4suggesting that some protective immunity to S. aureus © Jack Levy, Laurent Licini, Edwige Haelterman, Philippe Moris, Pascal Lestrate, Silvia Damaso, Pascale Van Belle, and Dominique Boutriau *Correspondence to: Dominique Boutriau, MD; Email: dominique.boutriau@gsk.comSubmitted: 08/21/2014; Revised: 11/03/2014; Accepted: 11/16/2014 http://dx.doi.org/10.1080/21645515.2015.1011021 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
full protocol is available at http://www.gsk-clinicalstudyregister.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Lancet 2006; 368:874-85; PMID:16950365; http://dx.doi.org/10.1016/S0140-6736(06)68853-3 3. WHO.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Available at: http://www.who.int/ mediacentre/factsheets/fs194/en/ 4.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Lancet 2004; 364:703-5; PMID:15325835; http://dx.doi.org/ 10.1016/S0140-6736(04)16897-9 5.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Front Cell Infect Microbiol 2012; 2:16; PMID:22919608; http://dx.doi.org/10.3389/fcimb.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Microbiol Rev 2004; 17:218-34;PMID:14726462; http://dx.doi.org/10.1128/CMR.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Infect Dis 2008; 198:125-33; PMID:18544012; http://dx.doi.org/10.1086/588825 12.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Biol Chem 2005; 280:2020-7; PMID:15542591; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Nat Rev Immunol 2006; 6:465-75; PMID:16724100;http://dx.doi.org/10.1038/nri1853 15.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Curr Opin Microbiol 2012;15:92-9; PMID:22088393; http://dx.doi.org/10.1016/ j.mib.2011.10.012 18.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Nat Rev Microbiol 2006; 4:295-305; PMID:16541137; http://dx.doi.org/ 10.1038/nrmicro1384 19.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Immunol 2011; 186:6585-96; PMID:21525381; http://dx.doi.org/10.4049/ jimmunol.1002794 20.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Vaccine 2012; 30:2921-7; PMID:22115633; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Infect Dis Clin North Am 2009; 23:153-71; PMID:19135920; http://dx.doi.org/ 10.1016/j.idc.2008.10.005 22.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Infect Dis 2012; 54:560-7; PMID:22186773; http://dx.do i.org/10.1093/cid/cir828 23.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
N Engl J Med 2002; 346:491-6; PMID:11844850; http://dx.doi.org/ 10.1056/NEJMoa011297 24.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Vaccine 2009; 28:256-60; PMID:19799842; http://dx.doi.org/10.1016/j.vaccine.2009.09.088 26.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
JAMA2013; 309:1368-78; PMID:23549582; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Hum Vaccin 2010; 6:857-9; PMID:20930569; http://dx.doi.org/10.4161/hv.6.10.12469 28.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Hum Vac- cin Immunother 2012; 8:1585-94; PMID:22922765; http://dx.doi.org/10.4161/hv.21872 29.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Infect Immun 2005; 73:3502-11; PMID:15908379; http://dx.doi.org/10.1128/ IAI.73.6.3502-3511.2005 31.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Infect Dis 2001; 183:160-3; PMID:11078484; http://dx.doi.org/10.1086/317646 32.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
The expression of alpha-haemolysin is required for Staphylococcus aureus phagosomal escape after internalization in CFT-1 cells.Cell Microbiol 2008; 10:1801-14; PMID:18466345; http://dx.doi.org/10.1111/j.1462-5822.2008.01166.x 35.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
PLoS One 2008; 3:e1409; PMID:18183290;http://dx.doi.org/10.1371/journal.pone.0001409 36.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
"Roles for ﬁbrinogen,immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005; 57:804-18; PMID:16045623;http://dx.doi.org/10.1111/j.1365-2958.2005.04731.x 37.",Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Vaccine Immunol 2013; 20:1338-40; PMID:23803901; http://dx.doi.org/10.1128/CVI.00275-13 38.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Infect Dis 2012; 206:915-23; PMID:22807524; http://dx.doi.org/10.1093/infdis/jis462 39.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Infect Dis 2013; 56:1554-61; PMID:23446627; http://dx.doi.org/10.1093/cid/ cit123 40.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
PLoS One 2012; 7: e38567; PMID:22701668; http://dx.doi.org/10.1371/ journal.pone.003856741.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Infect Dis 2010; 202:1050-8; PMID:20726702; http://dx.doi.org/ 10.1086/656043 42.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Vaccine Immunol 2014; 21:622-7;PMID:24574539; http://dx.doi.org/10.1128/ CVI.00051-14 43.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Infect Immun 2014; 82:83-91; PMID:24126523; http://dx.doi.org/10.1128/IAI.01050-13 44.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Infect Immun 2008; 76:5738- 44; PMID:18809660; http://dx.doi.org/10.1128/ IAI.00874-08 45.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Vaccine Immunol 2010;17:1746-52; PMID:20826613; http://dx.doi.org/ 10.1128/CVI.00162-10 46.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
PLoSOne 2008; 3:e2206; http://dx.doi.org/10.1371/ journal.pone.0002206 47.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the ﬁbrinogen-binding domain of clumping factor A. Infect Immun 2010; 78:4234- 42; PMID:20679443; http://dx.doi.org/10.1128/IAI.00447-10 48.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/ 10.1016/S0140-6736(07)61297-5 50.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
PLoS One 2008; 3:e1665; PMID:18301743; http://dx.doi.org/10.1371/journal.pone.0001665 51.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Vaccine 2011; 29:2461-73; PMID:21256188; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Vaccine Immunol2011; 18:835-43; http://dx.doi.org/10.1128/ CVI.00480-10 53.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Vaccine Immunol 2014; 21:56- 65; PMID:24173029; http://dx.doi.org/10.1128/CVI.00430-13 54.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Vaccine 2004; 22:880-7; PMID:15040941; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Pediatr 1992; 120:184-9; PMID:1735812; http://dx.doi.org/10.1016/S0022-3476(05)80424-X 56.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Drugs 2012; 72:2407-30; PMID:23231026; http://dx.doi.org/10.2165/ 11209580-000000000-00000 57.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Expert Rev Vaccines 2009; 8:1479- 500; PMID:19863240; http://dx.doi.org/10.1586/ erv.09.113 58.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 inﬂuenza vac- cines: a randomized controlled phase 1/2 trial in adults.J Infect Dis 2010; 201:1644-53; PMID:20423222; http://dx.doi.org/10.1086/652701 59.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Lancet Infect Dis 2013; 13:485-96;PMID:23518156; http://dx.doi.org/10.1016/S1473- 3099(13)70046-X 60.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Infect Dis 2002; 186:1848-51; PMID:12447774; http://dx.doi.org/10.1086/345763 67.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Vaccine 2011; 29:4881-90; PMID:21549783; http://dx.doi.org/10.1016/j.vaccine.2011.04.053 68.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Vaccine Immunol 2012; 19:1641- 50; PMID:22896688; http://dx.doi.org/10.1128/CVI.00354-12 69.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
PLoS Pathog 2009; 5: e1000703; PMID:20041174; http://dx.doi.org/ 10.1371/journal.ppat.1000703 70.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Int Immu- nol 2009; 21:105-12; PMID:19088064; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Ann N Y Acad Sci 2011; 1246:34-40;PMID:22236428; http://dx.doi.org/10.1111/j.1749- 6632.2011.06280.x 72.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
"J Exp Med 2009; 206:1291-301; PMID:19487419; http://dx.doi.org/10.1084/jem.20082767 73. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H,Samarina A, Janniere L, et al.",Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Exp Med 2008; 205:1543-50; PMID:18591412; http://dx.doi.org/10.1084/jem.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Infect Dis 2001; 33:1412-6; PMID:11565083; http://dx.doi.org/10.1086/322656 75.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Invest Dermatol 2001; 116:658-63; PMID:11348452; http://dx.doi.org/ 10.1046/j.0022-202x.2001.01331.x 76.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
N Engl J Med 2002; 347:1151-60; PMID:12374875; http://dx.doi.org/10.1056/NEJMoa 021481 77.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Invest Dermatol 2009; 129:2175-83; PMID:19295614; http://dx.doi.org/10.1038/jid.2009.65 78.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Infect Immun 2011; 79:1615-22; PMID:21245272; http://dx.doi.org/10.1128/IAI.00958-10 80.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Clin Exp Allergy 2005; 35:1088-95; PMID:16120092; http://dx.doi.org/ 10.1111/j.1365-2222.2005.02295.x 81.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Clin Immunol 2011; 31:443-54;PMID:21174144; http://dx.doi.org/10.1007/s10875- 010-9490-6 82.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Hum Vaccin Immunother 2013; 9:1512-22; PMID:23571166; http://dx.doi.org/ 10.4161/hv.24504 83.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
BMC Infect Dis 2013; 13:348; PMID:23890405; http://dx.doi.org/ 10.1186/1471-2334-13-348 84.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Nat Rev Immunol 2011;11:505-18; PMID:21720387; http://dx.doi.org/ 10.1038/nri301085.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Annu Rev Immunol 2009; 27:485-517; PMID:19132915; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Infect Immun 2011; 79:4210-7; PMID:21788380; http://dx.doi.org/10.1128/IAI.05286-11 89.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Nature 2012; 484:514-8; PMID:22466287;http://dx.doi.org/10.1038/nature10957 90.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Infect Dis 2013; 208:1953- 61; PMID:23904292; http://dx.doi.org/10.1093/ infdis/jit365 91.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Vaccine 2008; 26:1375-86;PMID:18272264; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
Sci- ence 2011; 332:974-7; PMID:21512004; http://dx.doi.org/10.1126/science.1206095 94.,OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
J Immunol 2013; 190:3417-26; PMID:23460735; http://dx.doi.org/10.4049/jimmunol.1202563 95.,Non-OADS,/arxiv_data1/oa_pdf/16/c3/khvi-11-03-1011021.PMC4514337.pdf
"Naturally occurring human PhtD-binding antibody was puri- ﬁed from a commercial pooled serum (obtained from © Sano ﬁPasteur *Correspondence to: Roger H Brookes; Email: Roger.Brookes@sano ﬁpasteur.com Submitted: 01/30/2015; Revised: 03/20/2015; Accepted: 04/04/2015 http://dx.doi.org/10.1080/21645515.2015.1039210 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Lancet 2009; 374:893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6 2 .,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Curr Opin Immunol 2011; 23:407-13; PMID:21514128; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Paediat Respir reviews 2012; 13:258-64; PMID:23069126; http://dx.doi.org/ 10.1016/j.prrv.2011.12.001 5.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Clin Microbiol Infect: Off Pub Eur Soc Clin MicrobiolInfect Dis 2012; 18 Suppl 5:25-36; PMID:22862432; http://dx.doi.org/10.1111/j.1469- 0691.2012.03938.x 6.,OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Infect Immun 2014; 82:1683- 91; PMID:24491577; http://dx.doi.org/10.1128/IAI.00699-137.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
"Vaccine 2012; 30:2900-7; PMID:22349524; http://dx.doi.org/ 10.1016/j.vaccine.2012.02.023 8 .A d a m o uJ E ,H e i n r i c h sJ H ,E r w i nA L ,W a l s hW , Gayle T, Dormitzer M, Dagan R, Brewah YA, Bar- ren P, Lathigra R, et al.",Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Infect Immun 2001; 69:949-58; PMID:11159990; http://dx.doi.org/10.1128/IAI.69.2.949-958.2001 9.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Clin Microbiol Infect: Off Pub Eur Soc Clin Microbiol Infect Dis 2013; 19:E551- 8; PMID:24255996; http://dx.doi.org/10.1111/1469-0691.12286 10.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Vaccine 2009; 27:4615-21; PMID:19524618; http://dx.doi.org/10.1016/j.vaccine.2009.05.071 11.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
FEMS Microbiol Lett 2006; 262:14-21; PMID:16907734; http://dx.doi.org/10.1111/j.1574-6968.2006.00360.x 12.,OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Infect Immun 2013; 81:3781-92; PMID:23897609; http://dx.doi.org/ 10.1128/IAI.00313-13 13.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Infect Immun 2011; 79:238-45; PMID: 20956575; http://dx.doi.org/10.1128/IAI.00378-10 14.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Vaccine 2014; 32:6838-46; PMID:24607003;http://dx.doi.org/10.1016/j.vaccine.2014.02.052 17.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
Vaccine 2015; 33:577-84; PMID:24176494;http://dx.doi.org/10.1016/j.vaccine.2013.10.052Table 2.,Non-OADS,/arxiv_data1/oa_pdf/e4/15/khvi-11-07-1039210.PMC4514344.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7a/20/dddt-9-3677.PMC4514347.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 3677–3683Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3677Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S8675 0relationship between UgT1a1*6/*28  polymorphisms and severe toxicities in chinese  patients with pancreatic or biliary tract cancer  treated with irinotecan-containing regimens chen Yang1 Ying liu1 Wen-qi Xi1 chen-fei Zhou2 Jin-ling Jiang1 Tao Ma1 Zheng-bao Ye1 Jun Zhang1 Zheng-gang Zhu1,2 1Department of Oncology, ruijin  hospital, shanghai Jiaotong University  school of Medicine, shanghai, People’s  republic of china; 2Department  of surgery, shanghai institute of  Digestive surgery, ruijin hospital,   shanghai Jiaotong University  school of Medicine, shanghai,   People’s republic of chinaPurpose:  The aim of this retrospective study was to investigate the relationship between  UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer  receiving irinotecan-containing regimens as the second- or third-line chemotherapy.",Non-OADS,/arxiv_data1/oa_pdf/7a/20/dddt-9-3677.PMC4514347.pdf
"A fluoropyrimidine-based regimen is commonly used for gemcitabine-refractory  patients.4 Irinotecan, an inhibitor of DNA topoisomerase I, demonstrated potent correspondence: Jun Zhang Department of Oncology, ruijin  hospital, shanghai Jiaotong University  school of Medicine, number 197,  ruijin er road, shanghai 200025,  People’s republic of china Tel +86 21 6437 0045 Fax +86 21 6437 3909 email junzhang10977@sjtu.edu.c n Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Y ang et al Running head recto: Relationship between UGT1A1*6/*28 polymorphisms and toxicities DOI: http://dx.doi.org/10.2147/DDDT.S86750",Non-OADS,/arxiv_data1/oa_pdf/7a/20/dddt-9-3677.PMC4514347.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/7a/20/dddt-9-3677.PMC4514347.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/7a/20/dddt-9-3677.PMC4514347.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5c/db/vhrm-11-417.PMC4514348.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pVascular Health and Risk Management 2015:11 417–425Vascular Health and Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  417ORiginal ReseaRcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/VHRM.S8450 7Hypoglycemia hospitalization frequency   in patients with type 2 diabetes mellitus:   a comparison of dipeptidyl peptidase 4 inhibitors  and insulin secretagogues using the French health  insurance database Bruno Detournay1 serge Halimi2,3 Julien Robert1 céline Deschaseaux4 sylvie Dejager5,6 1cemka-eval, Bourg-la Reine,   France; 2Department of Diabetology,   endocrinology and nutrition,   grenoble University Hospital  center, grenoble, France; 3University  Joseph Fourier, grenoble, France;   4novartis Pharma sas, Market access  Department, Rueil-Malmaison, France;   5novartis Pharma sas, Medical and  scientific affairs, Rueil Malmaison,   France; 6Department of Diabetology,   Metabolism and endocrinology, Pitié- salpétrière Hospital, Paris, France  correspondence: sylvie Dejager   novartis Pharma sas,   Medical affairs, 4 Rue lionel Terray,   92 506 Rueil-Malmaison, France   Tel +33 1 5547 6339   Fax +33 1 5547 6593   email sylvie.dejager@novartis.co mAim:  We aimed to compare the frequency of severe hypoglycemia leading to hospitalization  (HH) and emergency visits (EV) for any cause in patients with type 2 diabetes mellitus exposed  to dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4-i) versus those exposed to insulin secret - agogues (IS; sulfonylureas or glinides).",Non-OADS,/arxiv_data1/oa_pdf/5c/db/vhrm-11-417.PMC4514348.pdf
"Vascular Health and Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/vascular-health-and-risk-management-journa lVascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on  concise rapid reporting of clinical studies on the processes involved  in the maintenance of vascular health; the monitoring, prevention and  treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.",Non-OADS,/arxiv_data1/oa_pdf/5c/db/vhrm-11-417.PMC4514348.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5c/db/vhrm-11-417.PMC4514348.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a1/ef/ott-8-1761.PMC4514349.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 1761–1771OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1761Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S6076 2volasertib for AML: clinical use and patient  consideration Zhonglin Hao1 vamsi Kota2 1Cancer Center, Medical College of  Georgia, Georgia Regents University,   Augusta, GA, USA; 2winship Cancer  institute, emory University School of  Medicine, Atlanta, GA, USAAbstract:  Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients .65 years  of age.",Non-OADS,/arxiv_data1/oa_pdf/a1/ef/ott-8-1761.PMC4514349.pdf
"The favorable-risk AML patients generally are expected to  do well with postremission consolidation chemotherapy alone.5,6 Acute promyelocytic Correspondence: Zhonglin Hao Cancer Center, Medical College of  Georgia, Georgia Regents University,  1410 Laney walker Boulevard, Augusta,  GA 30912, USA email zhao@gru.ed uJournal name: OncoTargets and Therapy Article Designation: Review Y ear: 2015 Volume: 8 Running head verso: Hao and Kota Running head recto: Use of volasertib for AML DOI: http://dx.doi.org/10.2147/OTT.S60762",Non-OADS,/arxiv_data1/oa_pdf/a1/ef/ott-8-1761.PMC4514349.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/a1/ef/ott-8-1761.PMC4514349.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a1/ef/ott-8-1761.PMC4514349.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Epidemiology 2015:7 347–353Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  347MEthodologyopen access to scientific and medical research open Access Full text Article http: //dx.doi.org/10.2147/CLEP .S8416 2Existing data sources for clinical epidemiology:  the danish Patient Compensation Association  database Jens tilma1 Mette Nørgaard1 Kim lyngby Mikkelsen2 Søren Paaske Johnsen1 1department of Clinical Epidemiology,   Aarhus University hospital, Aarhus,   2danish Patient Compensation  Association, Copenhagen, denmarkAbstract:  Any patient in the Danish health care system who experiences a treatment injury can  make a compensation claim to the Danish Patient Compensation Association (DPCA) free of  charge.",Non-OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Other databases arising from compensation claims are  present internationally, eg, those in the People’ s Republic of  China described by Li et al,24 in New Zealand used by Davis  et al,25 and in the US used by Brown et al.26 Accessing DPCA data Data files are stored by the DPCA ( http://www.patienterstat - ningen.d k).",OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-epidemiology-journa lClinical Epidemiology is an international, peer-reviewed, open access,  online journal focusing on disease and drug epidemiology, identifica - tion of risk factors and screening procedures to develop optimal pre - ventative initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Available from: http://www.cdc.gov/nchs/ fastats/physician_visits.ht m. Accessed June  4, 2014.",OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
Available from: http://www.regioner.dk/aktuelt/temaer/fakta +om+reg ionernes +effektivitet +og+økonomi/kopi +af+fakta+om+sundhedsvæs enet.,OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Available from: http://www.sum.dk/Aktuelt/ Publikationer/ ~/media/Filer%20-%20Publikationer_i_pdf/2008/ UK_Healthcare_in_dk/pdf.ash x. Accessed March  18, 2014.",Non-OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
A vailable from:  http://patienterstatningen.dk/da/Udgivelser-og-tal/Statistik/ %/media/Files/ Statistik/Statistik%202012/hel%C3%A5rstal_2010_2012_12.ash x.,OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Available from: http://dpsd.demo.privatsite.dk/~/media/Foundry/Sites/ DPSD/Files/Informationsmateriale/rapportevaluering.ash x. Accessed  June 17, 2015.",OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Available from: http://dpsd.demo.privatsite.dk/ ∼/ media/Foundry/Sites/DPSD/Files/Aarsrapporter/2012_%C3%A5rsbe retning_dpsd_del_1_001.asp x. Accessed March  27, 2014.",OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
"Available from:  http://patienterstatningen.dk/da/Udgivelser-og-tal/~/media/Files/Artikler/ Rapport%2009032012.ash x. Accessed June 17, 2015.",Non-OADS,/arxiv_data1/oa_pdf/e2/d8/clep-7-347.PMC4514350.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 1743–1751OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1743Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S8651 9comparison of dynamic contrast-enhanced  magnetic resonance imaging with T2-weighted  imaging for preoperative staging of early  endometrial carcinoma linfeng Zheng1,2 sujuan Zheng3 Xiaochun Yuan1 Xifu Wang1 Zhuoli Zhang2 guixiang Zhang1 1Department of radiology, shanghai  First People’s hospital, shanghai Jiao  Tong University, shanghai, People’s  republic of china; 2Department  of radiology, Feinberg school of  Medicine, northwestern University,   chicago, il, Usa; 3Department of  Obstetrics and gynecology, Dengfeng  People’s hospital, Zhengzhou, People’s  republic of chinaPurpose:  This study aimed to compare dynamic contrast-enhanced magnetic resonance  imaging (DCE-MRI) with T2-weighted imaging (T2WI) for the preoperative staging of early  endometrial carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
"However, patients with endometrial car - cinoma that has advanced beyond stage IB require pelvic lymph node dissection and  other therapies.7,8 Additionally, studies have demonstrated that the overall 5-year  survival rate of endometrial carcinoma dramatically increases from 20% to 90% with correspondence: guixiang Zhang Department of radiology, shanghai  First People’s hospital, shanghai Jiao  Tong University, 100 haining road,  hongkou District, shanghai 200080,  People’s republic of china Tel +86 21 6324 0090 ext 4166 Fax +86 21 6324 0825 email guixiangzhang@sina.co mJournal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Zheng et al Running head recto: MRI for preoperative staging of early endometrial carcinoma DOI: http://dx.doi.org/10.2147/OTT.S86519",Non-OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
Kappa statistics were measured  to assess the agreement between T2WI- or DCE-MRI-based  staging and pathology-based staging according to previous  literature.12 All analyses were conducted using a web-based  statistical tool ( http://vassarstats.net /).,OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
"Available from: http://www.cancer.gov/types/uterin e. Accessed  May 17, 2015.",Non-OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
"Available  from: http://www.esmo.org/content/download/6604/115031/file/ ESMO-ACF-Endometrial-Cancer-Guide-for-Patients.pd f. Accessed  May 17, 2015.",Non-OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a7/38/ott-8-1743.PMC4514351.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/30/65/ijn-10-4581.PMC4514352.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 4581–4592International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4581OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8662 4Effect of liposomal fluidity on skin permeation  of sodium fluorescein entrapped in liposomes Thirapit Subongkot1 Tanasait Ngawhirunpat2 1Department of Pharmaceutical  Technology, Faculty of Pharmaceutical  Sciences, Burapha University,  Chonburi, Thailand; 2Department of  Pharmaceutical Technology, Faculty  of Pharmacy, Silpakorn University,  Nakhon Pathom, ThailandAbstract:  The purpose of this study was to investigate the effect of ultradeformable liposome  components, Tween 20 and terpenes, on vesicle fluidity.",Non-OADS,/arxiv_data1/oa_pdf/30/65/ijn-10-4581.PMC4514352.pdf
"This technique has been used to study membrane fluidity,20,21 the skin  penetration enhancement mechanism of penetration enhancers and nanocarriers,22,23  and antioxidant properties.24correspondence: Tanasait Ngawhirunpat Department of Pharmaceutical  Technology, Faculty of Pharmacy,  Silpakorn University, 6 Rajamankha Nai  Road, Muang, Nakhon Pathom 73000,  Thailand Tel +66 34 255 800 Fax +66 34 255 801 email ngawhirunpat_t@su.ac.t h Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Subongkot and Ngawhirunpat Running head recto: Effect of liposomal fluidity on skin permeation DOI: http://dx.doi.org/10.2147/IJN.S86624",Non-OADS,/arxiv_data1/oa_pdf/30/65/ijn-10-4581.PMC4514352.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/30/65/ijn-10-4581.PMC4514352.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/30/65/ijn-10-4581.PMC4514352.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3b/d0/ijwh-7-723.PMC4514353.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Women’s Health 2015:7 723–734International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  723OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S8631 4Maternal ophthalmic artery Doppler velocimetry  in pre-eclampsia in southwestern nigeria richard Busayo Olatunji1 ademola Joseph adekanmi1 Millicent Olubunmi Obajimi1 Olumuyiwa adebola roberts2 T emitope Olumuyiwa Ojo3 1Department of radiology,   2Department of Obstetrics and  gynaecology, University college  Hospital, Ibadan, Oyo state,   3Department of community  Medicine,  Obafemi awolowo  University Teaching  Hospital  complex,  Ile-Ife, Osun state,  nigeriaBackground:  Pre-eclampsia (PE) poses a serious challenge to maternal and fetal health in  Africa.",Non-OADS,/arxiv_data1/oa_pdf/3b/d0/ijwh-7-723.PMC4514353.pdf
"The  incidence of PE ranges from 5% to 10% worldwide.3 PE is a major cause of maternal  mortality and morbidity globally,3 and is documented in the literature to be more  prevalent in blacks.4,5 The prevalence of PE in Nigeria ranges between 2% and 16.7%.6,7  This condition contributes significantly to fetal wastage and perinatal mortality and  morbidity.4,5 Even though the pathogenesis of PE is unclear,8 and several hypotheses  have been proposed.2 The most widely accepted is that of endothelial dysfunction  leading to defective release of nitric oxide, prostacyclin, and other potent endogenous correspondence: ademola J adekanmi Department of radiology, college of  Medicine/University college Hospital,  University of Ibadan, Queen elizabeth  road, Ibadan, Oyo state nigeria Tel +23 480 3354 4856 email aadekanmi@comui.edu.n gJournal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2015 Volume: 7 Running head verso: Olatunji et al Running head recto: Maternal OAD velocimetry in pre-eclampsia DOI: http://dx.doi.org/10.2147/IJWH.S86314",Non-OADS,/arxiv_data1/oa_pdf/3b/d0/ijwh-7-723.PMC4514353.pdf
Available from: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3087154 /.,Non-OADS,/arxiv_data1/oa_pdf/3b/d0/ijwh-7-723.PMC4514353.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/3b/d0/ijwh-7-723.PMC4514353.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3b/d0/ijwh-7-723.PMC4514353.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/aa/9f/ijn-10-4621.PMC4514354.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 4621–4621International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4621Erratumopen access to scientific and medical research Open access Full text article http: //dx.doi.org/10.2147/IJN.S7982 7Journal name: International Journal of Nanomedicine Article Designation: Erratum Y ear: 2015 Volume: 10 Running head verso: Kwon et al Running head recto: Undetactable levels of genotoxicity of SiO2 nanoparticles DOI: http://dx.doi.org/10.2147/IJN.S79827 Undetactable levels of genotoxicity of SiO2 nanoparticles in in vitro  and in vivo tests [Erratum] Kwon JY, Kim HL, Lee JY, et al.",Non-OADS,/arxiv_data1/oa_pdf/aa/9f/ijn-10-4621.PMC4514354.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/aa/9f/ijn-10-4621.PMC4514354.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s,Non-OADS,/arxiv_data1/oa_pdf/aa/9f/ijn-10-4621.PMC4514354.pdf
"However, efforts to standardize meth- ods across settings cannot occur without access to the speciﬁc testing methodology,and vaccine manufacturers frequently treatKeywords: access to information law, intellectual property, transparency, vac- cine assays © Matthew Herder, Todd F Hatchette, Scott A Hal- perin, and Joanne M Langley*Correspondence to: Matthew Herder; Email: Matthew.Herder@dal.ca Submitted: 08/22/2014Accepted: 09/04/2014http://dx.doi.org/10.4161/21645515.2014.980194 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/e9/khvi-11-02-980194.PMC4514357.pdf
Clin Vaccine Immunol 2010; 17(7):1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.,Non-OADS,/arxiv_data1/oa_pdf/2e/e9/khvi-11-02-980194.PMC4514357.pdf
Clin Infect Dis2012; 54(11):1615-7; PMID:22437237; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2e/e9/khvi-11-02-980194.PMC4514357.pdf
Clin Infect Dis 2013; 56(10):1458-65;PMID:23386629; http://dx.doi.org/10.1093/cid/cit048 19.,Non-OADS,/arxiv_data1/oa_pdf/2e/e9/khvi-11-02-980194.PMC4514357.pdf
Clin Infect Dis 2008; 47(3):401-9; PMID:18558875; http://dx.doi.org/10.1086/589862 20.,Non-OADS,/arxiv_data1/oa_pdf/2e/e9/khvi-11-02-980194.PMC4514357.pdf
"Clin Vaccine Immunol 2012;19(8):1261-8; PMID:22718131; http://dx.doi.org/ 10.1128/CVI.00183-12 36. International Committee of Medical Journal Editors, Uniform Requirements for manuscripts submitted to biomedical journals: ethical considerations in the con-duct and reporting of research: Authorship and Con- tributorship, 2013, available at: http://www.icmje.org/ ethical_1author.html (last visited: Nov. 14, 2013).",Non-OADS,/arxiv_data1/oa_pdf/2e/e9/khvi-11-02-980194.PMC4514357.pdf
"3 © Sano ﬁPasteur MSD *Correspondence to: Emmanuelle Pr /C19eaud; Email: epreaud@spmsd.com Submitted: 08/13/2014; Revised: 11/05/2014; Accepted: 11/19/2014 http://dx.doi.org/10.1080/21645515.2015.1011561 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Rev MedMicrobiol 1993; 4:222–30; http://dx.doi.org/10.1097/ 00013542-199310000-00006 2.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Fam Prac 2002; 19:471-5; PMID:12356697; http://dx.doi.org/ 10.1093/fampra/19.5.471 4.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi.org/ 10.1056/NEJMoa0510166.,OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
J Med Virol 2003; 70:S24-S30; PMID:12627483; http://dx.doi.org/ 10.1002/jmv.10316 7.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Pain 2007; 128:148-56; PMID:17070998; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Clin Infect Dis 2007; 44:1280-8; PMID:17443464; http://dx.doi.org/10.1086/514342 9.,OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Clin J Pain 2002; 18:350-4; PMID:12441828; http://dx.doi.org/10.1097/ 00002508-200211000-00002 10.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
AMA Arch Derm 1957; 75:193-6;PMID:13393787; http://dx.doi.org/10.1001/ archderm.1957.01550140037006 11.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Arch Internal Med 1995;155:1605-9; PMID:7618983; http://dx.doi.org/ 10.1001/archinte.1995.00430150071008 12.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Clin Infect Dis 2004; 39:342-8; PMID:15307000; http://dx.doi.org/ 10.1086/421942 13.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
J Pain 2005; 6:356-63; PMID:15943957; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
J Public Bealth 2012; 20:441-51; PMID:22822293; http://dx.doi.org/10.1007/s10389-011-0481-8 15.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Clin Infect Dis 2012; 54:922-8; PMID:22291101; http://dx.doi.org/ 10.1093/cid/cir970 16.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Drugs Aging 2007; 24:1-19; PMID:17233544; http://dx.doi.org/10.2165/00002512-200724010-00001 18.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Vaccine 2007; 25:8326-37;PMID:17980938; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
"J Clin Epidemiol 1998; 51:667-76; PMID:9743315;http://dx.doi.org/10.1016/S0895-4356(98)00036-5 20. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neural- gia.",OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Age Ageing 2006; 35:132-7; PMID:16431855;http://dx.doi.org/10.1093/ageing/afj048 21.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
BMC Health Ser Res 2013; 13:359; PMID:24070414; http://dx.doi.org/10.1186/1472-6963-13-359 23.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Vaccine 2012; 30:2795-800; PMID:21964056;http://dx.doi.org/10.1016/j.vaccine.2011.09.079 24.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
J Med Econom 2010; 13:537-51; PMID:20707768; http://dx.doi.org/10.3111/13696998.2010.502854 25.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Expert Rev Pharmacoeconom Outcomes Res 2013;13:393-406; PMID:23537397; http://dx.doi.org/ 10.1586/erp.13.19 26.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Cost Eff Resour Alloc 2010; 8:7; PMID:20433704; http://dx.doi.org/10.1186/1478- 7547-8-7 27.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Vaccine 2014; 26:1645-53; http://dx.doi.org/ 10.1016/j.vaccine.2014.01.058 31.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
"Hum Vac- cines Immunother 2014; 10:2048-61; PMID:25424815; http://dx.doi.org/10.4161/hv.28670 33. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ.",OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
"Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.Human vaccines 2008; 4:238-45; PMID:18382137; http://dx.doi.org/10.4161/hv.4.3.5686 36.",Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
BMC Infect Dis 2011; 11:173;PMID:21679419; http://dx.doi.org/10.1186/1471- 2334-11-173 38.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
J Infect Dis 2012; 206:190-6; PMID:22669900; http://dx.doi.org/10.1093/infdis/ jis334 39.,OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
J Pain 2010b; 11:1211- 21; http://dx.doi.org/10.1016/j.jpain.2010.02.020 41.,OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
BMC Public Health 2008; 8:272;PMID:18673545; http://dx.doi.org/10.1186/1471- 2458-8-272 45.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Vaccine 2001; 19:3076-90; PMID:11312002; http://dx.doi.org/10.1016/S0264-410X(01)00044-5 48.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
J Clin Virol 2003; 26:277-89; dis- cussion 91-3; PMID:12637076; http://dx.doi.org/ 10.1016/S1386-6532(03)00005-2 51.,OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
BMC Infect Dis2011; 11:302; PMID:22044665; http://dx.doi.org/ 10.1186/1471-2334-11-302 53.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
"http://www.kbv.de/ html/arztgruppen_ebm.php, 2013 54.",Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
Vaccine 2012; 30:2047-50; PMID:22285632; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/d0/de/khvi-11-04-1011561.PMC4514364.pdf
"vorsters@uantwerpen.be Submitted: 10/06/2014 Accepted: 10/16/2014 http://dx.doi.org/10.4161/21645515.2014.995058 This is an Open Access article distributed under theterms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/ 10.1016/S0140-6736(09)61248-4 3.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
CancerPrevention Research 2009; 2:868-78; PMID:19789295; http://dx.doi.org/10.1158/1940- 6207.CAPR-09-0031 4.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
New England Journal of Medicine 2007; 356:1915-27; PMID:17494925; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Vaccine 2012; 30 (Suppl 5):F83-7; PMID:23199968; http://dx.doi.org/10.1016/j.vaccine.2012.04.106 6.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Vaccine 2012; 30(Supplement 5):F123-F38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Journal of Infectious Diseases 2009; 199:926-35;PMID: 19236279; http://dx.doi.org/10.1086/597307 10.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Vaccine 2010; 28:6247-55; PMID:20643092; http://dx.doi.org/10.1016/j.vaccine.2010.07.007 11.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Cancer Discovery 2011; 1:408-19; PMID:22586631; http://dx.doi.org/10.1158/2159- 8290.CD-11-0131 12.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Cancer Epidemiology Biomarkers & Prevention 2010; 19:1585-94; PMID:20530494; http://dx.doi.org/10.1158/1055- 9965.EPI-09-1235 13.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
The Lancet 2009; 373:1949-57; PMID:19493565; http://dx.doi.org/ 10.1016/S0140-6736(09)60691-7 14.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Br J Cancer 2006; 95:1459-66; PMID:17117182;http://dx.doi.org/10.1038/sj.bjc.6603469 15.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Vaccines2014; 2:422-62; http://dx.doi.org/10.3390/ vaccines2020422 17.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Gynecol Oncol 2008; 109:59-64; PMID:18255129; http://dx.doi.org/10.1016/j.ygyno.,OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Lancet Oncol 2014; 15:172-83; PMID:24433684;http://dx.doi.org/10.1016/S1470-2045(13)70570-9 20.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Eur J Clin Microbiol 2012; 31:627-40; PMID:21818524; http://dx.doi.org/ 10.1007/s10096-011-1358-z 22.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
Clin Epidemiol 2013; 5:67-79; PMID:23516174;http://dx.doi.org/10.2147/CLEP.S39799 23.,Non-OADS,/arxiv_data1/oa_pdf/45/3a/khvi-11-02-995058.PMC4514373.pdf
"Furthermore, a needle-free intranasal(IN) inﬂuenza vaccine is an attractive approach providing © 2015 Crown Copyright *Correspondence to: Rebecca J Cox; Email: rebecca.cox@k2.uib.noSubmitted: 08/06/2014; Revised: 09/23/2014; Accepted: 10/01/2014 http://dx.doi.org/10.4161/21645515.2014.988554 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Available from: http://www.who.int/inﬂuenza/human_animal_interface/Inﬂuenza_Summary_ IRA_HA_interface_26January2015.pdf.pdf?ua=1 2.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Science 2013; 340:1459- 63; PMID:23641061; http://dx.doi.org/10.1126/science.1229455 4.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Science 2012; 336:1534-41; PMID:22723413; http://dx.doi.org/10.1126/science.1213362 5.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Expert Rev Vaccin 2009; 8:493-8; PMID:19348564; http://dx.doi.org/ 10.1586/erv.09.3 6.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
N Engl J Med 2004; 350:896-903; PMID:14985487; http://dx.doi.org/10.1056/ NEJMoa030595 7.,OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
PloS One 2009; 4:e6999; PMID:19756141; http://dx.doi.org/10.1371/journal.pone.0006999 8.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Vaccine 2010; 28:3080-5;PMID:20197136; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
J Immu- nol 2007; 178:2171-81; http://dx.doi.org/10.4049/ jimmunol.178.4.2171 11.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Vaccine 2011; 29:4973-82; PMID:21600260;http://dx.doi.org/10.1016/j.vaccine.2011.04.094 12.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
PloS One 2011; 6:e26973; PMID:22069479; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
J Hyg 1972; 70:767-77; PMID:4509641; http://dx.doi.org/10.1017/S0022172400022610 14.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Nat Rev Microbiol 2004; 2:842-7;PMID:15378048; http://dx.doi.org/10.1038/ nrmicro979 16.,OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Expert Rev Vaccin 2013; 12:767-77; PMID:23885822; http://dx.doi.org/ 10.1586/14760584.2013.811178 17.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Hum Vaccin 2011; 7 Suppl:41-50;PMID:21266846; http://dx.doi.org/10.4161/hv.7.0.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Hum Vaccin 2007; 3:146-8; PMID:17643065; http://dx.doi.org/10.4161/hv.3.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Vaccine 2009; 27:1087-92; PMID:19100806; http://dx.doi.org/10.1016/j.vaccine.2008.11.108 20.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Vaccine 2007; 25:5467-84; PMID:17227687; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Inﬂuenza Other Respir Viruses 2009; 3:107- 17; PMID:19453487; http://dx.doi.org/10.1111/j.1750-2659.2009.00082.x 22.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
J Infect Dis 2006; 194:1040-3; PMID:16991078; http://dx.doi.org/10.1086/507709 23.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Nature 2009; 461:788-92; PMID:19776740; http://dx.doi.org/10.1038/nature08476 26.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
"J Immunol 2014; 192:492-502; http://dx.doi.org/10.4049/jimmunol.1301812 28. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. H5N1 VirusAttachment to Lower Respiratory Tract.",Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
Science 2006; 312:399; PMID:16556800; http://dx.doi.org/ 10.1126/science.1125548 29.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/khvi-11-05-988554.PMC4514375.pdf
